
==== Front
Mol Cancer
Mol Cancer
Molecular Cancer
1476-4598
BioMed Central London

2103
10.1186/s12943-024-02103-x
Review
Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance
Dai Wei 123
Zhou Jianwei 2195045@zju.edu.cn

4
Chen Ting tchen2013@zju.edu.cn

123
1 https://ror.org/00a2xv884 grid.13402.34 0000 0004 1759 700X Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009 China
2 Zhejiang Provincial Clinical Research Center for CANCER, Hangzhou, Zhejiang 310009 China
3 https://ror.org/00a2xv884 grid.13402.34 0000 0004 1759 700X Cancer Center of Zhejiang University, Hangzhou, Zhejiang 310009 China
4 https://ror.org/059cjpv64 grid.412465.0 Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
16 9 2024
16 9 2024
2024
23 20123 7 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Ovarian cancer (OC) is one of the most prevalent and lethal gynecological malignancies, with high mortality primarily due to its aggressive nature, frequent metastasis, and resistance to standard therapies. Recent research has highlighted the critical role of extracellular vesicles (EVs) in these processes. EVs, secreted by living organisms and carrying versatile and bioactive cargoes, play a vital role in intercellular communication. Functionally, the transfer of cargoes orchestrates multiple processes that actively affect not only the primary tumor but also local and distant pre-metastatic niche. Furthermore, their unique biological properties position EVs as novel therapeutic targets and promising drug delivery systems, with potential profound implications for cancer patients.

This review summarizes recent progress in EV biology, delving into the intricate mechanisms by which EVs contribute to OC metastasis and drug resistance. It also explores the latest advances and therapeutic potential of EVs in the clinical context of OC. Despite the progress made, EV research in OC remains in its nascent stages. Consequently, this review presents existing research limitations and suggests avenues for future investigation. Altogether, the review aims to elucidate the critical roles of EVs in OC and spotlight their promising potential in this field.

Keywords

Ovarian cancer
Extracellular vesicles
Metastasis
Chemotherapy resistance
National Natural Science Foundation of China82173220 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Ovarian cancer (OC) is the second leading cause of global gynecologic cancer deaths [1]. Epithelial ovarian cancers (EOC) account for over 90% of ovarian tumors, with high-grade serous carcinoma being the most prevalent variant, typically originating from the distal end of the fallopian tube [2]. While cervical cancer has seen a reduction in morbidity and mortality due to decreased HPV infection rates and effective HPV vaccination [3], and most endometrial cancers can be cured by hysterectomy due to early clinical manifestations like postmenopausal bleeding [4], ovarian cancer remains insidious with no typical early symptoms, leading to late-stage diagnosis and posing significant threats to women’s lives [5]. The standard first-line treatment of ovarian cancer includes extensive debulking surgery, combined with platinum- and taxane-based chemotherapy, with or without the angiogenesis inhibitor bevacizumab [6]. The introduction of Poly (ADP-ribose) polymerase inhibitors (PARPis) has brought about a significant change in the treatment of ovarian cancer, opening a new era of ovarian cancer maintenance therapy. Several phase III clinical randomized controlled trials have shown that PARPis significantly prolong progression-free survival of ovarian cancer patients, especially in patients with BRCA gene mutation and/or homologous recombination deficiency (HRD) positivity, making them the preferred first-line maintenance therapy for some ovarian cancer patients [7–11]. Immunosuppressants and antibody-drug conjugates are also under investigation, offering new therapeutic hope [12]. An interim analysis of the Phase III DUO-O study presented at the 2023 American Society of Clinical Oncology annual meeting demonstrated for the first time that immunotherapy can provide tangible benefits in first-line maintenance therapy for ovarian cancer, altering the previously unsuccessful trend of immunotherapy in this disease [13]. Despite significant progress in surgical techniques, chemotherapy, and maintenance therapy over recent decades, more than 70% of patients with advanced disease will still experience recurrence after completion of standard initial therapy [14, 15]. And with more lines of treatment, patients develop multidrug resistance, leading to shorter remission periods and resulting in a 50% relative survival rate at five years globally [16]. Therefore, metastasis and chemotherapy resistance in ovarian cancer remain major obstacles to the treatment of ovarian cancer.

Extracellular vesicles (EVs) are cell-derived particles encapsulated by a lipid bilayer and incapable of self-replication. Depending on the biogenesis pathway, exosomes refer to EVs released from the interior of the cell via multivesicular vesicles, whereas ectosomes (a.k.a., microvesicle, microparticle) refer to EVs germinating from the surface of the cell. Moreover, some types of EVs are produced during specific cellular processes. Migrasomes are 500–3000 nm EVs left behind by migrating cells, while apoptotic bodies are formed by swelling and protrusion of apoptotic membranes during cell death [17]. In addition, based on diameter, small EVs typically refer to particles less than 200 nanometers in diameter, which includes small ectosomes and exosomes [18]. Among them, exosomes have been most intensively studied due to their small average particle size, narrow range of particle size distribution, complex composition and diverse functions [19] (Fig. 1). EVs carry a wide variety of cargoes, including RNAs, proteins, lipids, and DNA, and serve as important intercellular communication mediators that regulate gene expression profiles in the target cells [20]. In addition to delivering cargo to target cells to facilitate intercellular communication, EVs are involved in processes such as cell differentiation and proliferation, angiogenesis and immune signaling [21]. In recent years, an increasing body of research has emphasized the pivotal role of EVs in various aspects of cancer biology, including carcinogenesis, metastasis, drug resistance, and tumor immune response [22]. Furthermore, EVs have emerged as promising liquid biopsy markers due to their tumor-associated content and stable presence in body fluids, and have become a frontier hot spot in the field of tumor marker research, which is expected to help the accurate diagnosis and treatment of cancer [23].

Following this, the exploration will focus on the significance of tumor- and tumor microenvironment-derived EVs in orchestrating OC metastasis. The multifaceted roles of EVs in OC drug resistance will then be examined in greater depth, encompassing the intricate mechanisms of resistance and the potential therapeutic strategies targeting EVs. This in-depth discussion aims to elucidate the pivotal roles of EVs in the progression and treatment of OC.

Fig. 1 Biogenesis of extracellular vesicles. Exosomes are produced via the endosomal pathway. The plasma membrane invaginates to form early endosomes, which can exchange materials with the Golgi apparatus or fuse with each other to form late endosomes. These late endosomes transition into multivesicular bodies (MVBs). MVBs can fuse with lysosomes for degradation or with the plasma membrane to release exosomes. Apoptotic bodies, large oncosomes, and ectosomes are formed through cell budding. Migrasomes are vesicular structures generated at the tips or branches of contractile fibers during cell migration. Released extracellular vesicles (EVs) can directly bind to the cell surface, fuse with the cell membrane to release their contents into the cytoplasm, or be internalized by cells through endocytosis

How do EVs affect ovarian cancer metastasis?

The metastasis of ovarian cancer is a dynamic and multifaceted process, requiring cancer cells to undergo a series of steps in the invasion-metastasis cascade. Initially, ovarian cancer cells from the primary lesion invade the extracellular matrix, locally invading to enable tumor cells to breach the basement membrane and vascular walls, subsequently entering blood or lymphatic vessels and thus accessing the circulatory system. Once tumor cells survive in the circulation system, they can potentially be transported to other parts of the body and establish in distant organs. Unlike most cancers that primarily metastasize through blood or lymphatic routes, the most common mode of ovarian metastasis is through implantation. Due to the lack of anatomical barriers, tumor cells can shed directly, implanting onto the surfaces of pelvic and abdominal organs, disseminating within the peritoneal cavity via peritoneal fluid [24] (Fig. 2).

EVs contribute to the aforementioned process of ovarian cancer metastasis by enhancing tumor cell invasiveness, promoting angiogenesis, modulating immunity, and inducing epithelial-mesenchymal transition. Additionally, prior to the formation of metastatic lesions, extracellular vesicles can flow within the circulatory system or peritoneal fluid, adjusting the microenvironment of distant organs, thereby inducing the formation of pre-metastatic niches and providing conducive conditions for the settlement and growth of ovarian cancer cells.

Fig. 2 Metastatic process of ovarian cancer. In situ ovarian cancer can metastasize via blood and lymphatic vessels. However, due to the lack of anatomical barriers between the peritoneal cavity and ovaries, cancer cells can directly shed and implant within the peritoneum, the most common site of metastasis. EVs can travel with ascites, impacting the peritoneum and promoting the formation of pre-metastatic niches, thereby facilitating further OC spread

Improve dissemination potential of primary tumor cells

Migration refers to the process by which tumor cells move from their original location to other sites, typically involving cell motility and directional movement. Invasion, on the other hand, describes the penetration of tumor cells through surrounding tissues or blood vessel walls to invade neighboring tissues or blood vessels. For tumor cells to invade, they must possess migratory capability. EVs exert regulatory influence over the signaling pathways and genetic expression within tumor cells, consequently amplifying their migratory proficiency and expediting the process of invasion.

Exosomal LRP1 promotes the migration of ovarian cancer cells. The low-density lipoprotein receptor-related protein 1 (LRP1) is a high molecular weight transmembrane receptor widely expressed on cell surfaces, primarily involved in endocytosis and regulation of signaling pathways [25]. Proteomic analysis of serum exosomes from epithelial ovarian cancer (EOC) patients revealed significantly elevated LRP1 levels compared to healthy volunteers. In vitro experiments demonstrated that patient-derived serum exosomes promoted ovarian cancer cell migration, possibly through the p-ERK/MMP2/MMP9 signaling pathway. Subsequent in vivo experiments further confirmed the impact of exosomal LRP1 on tumor migration. Additionally, prognostic analysis indicated that elevated levels of LRP1 may lead to shortened overall survival in EOC patients, suggesting the potential diagnostic value of circulating exosomal LRP1. However, further studies with expanded sample sizes are needed for validation [26].

EVs can also enhance the migration of ovarian cancer cells through the transfer of microRNA. M2 macrophages, particularly tumor-associated macrophages (TAMs), are predominant immune cells in the peritoneum [27]. The interaction between TAMs and tumor cells is pivotal in OC progression, with EVs occupying a crucial position as carriers of micro-messages in this process. In M2 exosomes, microarray analyses revealed an enrichment of miR-221-3p, which is transferred to ovarian cancer cells, directly suppressing cyclin-dependent kinase inhibitor 1B (CDKN1B) and promoting cell proliferation and migration. Decreased CDKN1B levels correlate with ovarian cancer progression and poor prognosis [28]. A separate study found that miR-106a-5p expression is markedly higher in ovarian cancer cells compared to normal cells. Tumor-derived EVs carrying miR-106a-5p inhibit KLF6, promoting OC cell proliferation and migration, thus driving cancer progression and metastasis [29]. Notably, exosomal miR-106a-5p has also been reported to promote tumorigenesis in other cancers such as nasopharyngeal carcinoma, hepatocellular carcinoma, and breast cancer [30–32].

In addition to directly promoting tumor growth and metastasis, more aggressive subpopulations can confer a metastatic phenotype to less aggressive subpopulations through exosomes. CD44 expression is higher in ovarian cancer cells with greater metastatic ability and in the exosomes they secrete. It was found that exosomal CD44 from highly metastatic HO8910PM cells could be transferred to low metastatic HO8910 cells, and that overexpression of CD44 promoted migration, invasion, and proliferation of HO8910 cells as a promoter of metastatic behavior. The ability of ovarian cancer to metastasize extensively may develop by transferring high metastatic capacity between tumor cells. However, the study’s reliability appears to be insufficient, given that it only experimented with a single ovarian cancer cell line [33].

Conversely, some EVs may inhibit malignant biological behaviors. Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), a member of the TNF superfamily, may mediate an anti-tumor effect on tumor-infiltrating macrophages [34]. Research demonstrated that exosomes from TWEAK-stimulated macrophages (TMs) attenuated the migration and invasion of EOC cells. TMs inhibit ovarian cancer invasion and metastasis both in vivo and in vitro by delivering exosomal miR-7 to epithelial ovarian cancer cells. miR-7, a tumor-suppressive microRNA, suppresses the activity of the EGFR/AKT/ERK1/2 signaling pathways in ovarian cancer cells. This study highlights TWEAK’s role in the enrichment of miR-7 in macrophages, although the precise mechanism by which TWEAK upregulates miR-7 remains undetailed [35].

Form pre-metastatic niche

The pre-metastatic niche (PMN) refers to the environment or conditions in distant organs that promote tumor cell colonization and growth before malignant tumor cells detach from the primary tumor site and spread through the blood or lymphatic system to these distant sites. The formation of the PMN is primarily driven by the secretion of EVs, cytokines, growth factors, and other signaling molecules [36]. In recent years, the role of EV-mediated PMN formation has garnered significant attention.

Current research on PMN focuses more on extracellular matrix remodeling and reprogramming. During EVs remodeling of stromal cells at the site of metastasis to facilitate metastasis, it is important to induce macrophage polarization and convert some normal stromal cells into CAFs. Macrophages are typically classified into two main groups, namely classically activated macrophages (M1) and alternatively activated macrophages (M2), with M1 macrophages exhibiting pro-inflammatory activity and M2 macrophages displaying pro-tumorigenic activity [37]. TAMs are a subset of immune cells in the TME and are involved in tumorigenesis, progression and metastasis. TAMs are predominantly of the M2 type and are situated in the TME, where they exert influence on metastasis in multiple cancer types through their interactions with cancer cells [38]. Studies have identified that circATP2B4-containing EVs generated by EOC cells are abnormally highly expressed in ovarian cancer metastasis and promoted M2 macrophage polarization through the miR-2-532p/SREBF3 axis, thereby promoting EOC metastasis [39]. In addition, miR-181c-5p is highly expressed in EVs from hypoxic EOC cells, leading to increased M2 polarization of TAMs and ultimately promoting EOC growth and metastasis. Further investigation revealed that miR-181c-5p upregulates HOXA10 by targeting KAT2B and activate the JAK1 / STAT3 signaling pathway, thereby promoting the polarization of TAMs [40].

EVs can also reprogram stromal cells in the PMN, including CAFs, into tumor-promoting phenotypes. Research has shown that exosomal miR-141, highly secreted by ovarian cancer cells, can reprogram mesenchymal fibroblasts into pro-inflammatory CAFs, thus promoting metastatic colonization. Additionally, tumor-secreted exosomal miR-141 activates tumor-stromal interactions and promotes PMN formation by mediating the YAP1/GROα/CXCRs signaling pathway [41]. Furthermore, OC-derived EVs were observed to transport miR-630 into NFs and through the KLF6/NF-κB axis, thereby promoting CAFs activation and facilitating ovarian cancer invasion and metastasis [42]. However, further in vivo experiments are required to further fully elucidate the role of miR-630/KLF axis in ovarian cancer.

The peritoneum is a thin membrane that covers the surfaces of intra-abdominal organs and the inner side of the abdominal wall. The shedding of ovarian cancer cells from the primary tumor and their carriage to the omentum and peritoneum through the physiological movement of peritoneal fluid is recognized as one of the most common metastatic routes for epithelial ovarian cancer [43]. The development of metastasis is not a random event, and it only occurs when tumor cells and organs are compatible, according to Stephan Paget’s seed-soil theory. In the microenvironment of the peritoneal cavity of ovarian cancer, human peritoneal mesothelial cells (HPMCs) are continuous monolayers of cells lining the peritoneal cavity, and the mesothelial layer composed of HPMCs is a natural barrier and an important line of defense for the body to resist the metastasis of tumors in the peritoneal cavity [44]. One of the critical steps in successful metastasis of ovarian cancer is the attachment and effective interaction of cancer cells with HPMCs to form secondary tumors. Reports have suggested that tumor cells release EVs carrying high concentrations of MMP1 mRNA in ascites, which induce apoptosis in mesothelial cells and disrupt the mesothelial cell barrier, facilitating peritoneal metastasis. Moreover, MMP1 in EVs may be a prognostic biomarker because the level of MMP1 expression in tumor tissues is closely associated with the prognosis of patients with early-stage ovarian cancer [45].

Apart from directly stimulating mesothelial cell apoptosis, EVs can also remodel peritoneal mesothelial cells through the mesothelial-mesenchymal transition (MMT) pathway. The peritoneum serves as the first barrier for intra-abdominal organ defense, and under some circumstances such as inflammatory or traumatic stimuli, MMT occurs in mesothelial cells, which facilitates tumor peritoneal colonization [46]. The researchers applied ovarian cancer cell-derived EVs to mesothelial cells and found that the EVs could enter recipient mesothelial cells, induce the MMT phenotype and enhance cancer cell adhesion to mesothelial cells. Further studies demonstrated that LncRNA SPOCD1-AS from ovarian cancer EVs remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1 [47]. One study co-cultured exosomal annexin A2 (ANXA2) derived from ovarian cancer cells with HPMCs. ANXA2 from ovarian cancer cells could be transferred to HPMCs via exosomes, which not only promoted the migration, invasion, apoptosis, morphological changes and fibrosis of HPMCs, but also promoted MMT and extracellular matrix degradation of HPMCs through the PI5K/AKT/mTOR pathway, and ultimately facilitated peritoneal metastasis [48]. Another study reported that cancer-derived exosome circPUM1 effects on the peritoneum to upregulate the expression of NF-κB and MMP2 in mesothelial cells and induces MMT, thereby promoting peritoneal spread of the tumor [49].

Li et al. found that the EOC cells transfer the exosomal ITGA5B1/AEP complex to HPMCs, and these exosomes facilitate HPMCs proliferation and migration. And HPMCs ultimately favor EOC peritoneal metastasis through the FAK/Akt/Erk pathway and phosphorylation of EMT [50]. Additionally, EOC-derived exosomes can transfer CD44 to HPMCs, reprogramming them to a more EMT phenotype, thereby promoting cancer invasion and metastasis [51].

Fibronectin and vitronectin play crucial roles in the peritoneal dissemination of ovarian cancer. Exosomal miR-99a-5p from EOC cells promotes EOC cell invasion by upregulating fibronectin and vitronectin in HPMCs [52]. This underscores the intricate role of EVs in orchestrating ovarian cancer metastasis by modulating peritoneal mesothelial cells, offering a potential target for the treatment of ovarian cancer intraperitoneal metastasis.

The omentum, a structure composed of fat and connective tissue, is actually a part of the peritoneum. It hangs from the lower edge of the stomach, covering and protecting abdominal organs, and is a common and clinically significant site for ovarian cancer metastasis [53]. Lipids from omental adipocytes and cytokines released by omental fibroblasts and adipose mesenchymal stem cells promote the growth of ovarian tumor implants on the omentum [54].

Tumor-derived exosomes exhibit the capacity to reprogram omental macrophages. Relevant studies have shown that ETS1 enhances the translocation of tumor cell-derived exosomes to omental macrophages through the interaction of exosomal laminin with macrophage integrin αvβ5, laying the foundation for the establishment of PMN. Exosomes originating from ETS1-overexpressing ovarian cancer cells induce M2 polarization and upregulate CXCL5 and CCL2 expression in macrophages, fostering the pro-tumorigenic effects of omental macrophages and ultimately promoting ovarian cancer metastasis to the omentum. Subsequent analyses revealed that ETS1 drives ovarian cancer cells to release exosomes with higher levels of laminin, thus accelerating the pro-metastatic effects through the integrin αvβ5/AKT/Sp1 pathway [55].

As the main component of omental stromal cells, carcinoma-associated fibroblast (CAF) plays a key role in the omental metastasis of OC cells [56]. Tumor cells induce the activation of CAFs, which in turn promote tumor cell metastasis by secreting exosomes [57]. The transformation from normal fibroblasts (NFs) to CAFs results in a reduction of miR-29c-3p. Low miR-29c-3p levels in CAFs-derived exosomes contribute to the de-repression of MMP2, promoting an aggressive phenotype in OC cells and thus the spread of ovarian cancer in the peritoneal cavity [58].

The omentum, rich in adipose tissue, contains adipose-derived stem cells (ADSCs), a significant subpopulation of mesenchymal stem cells (MSCs) capable of secreting EVs [59]. While there are conflicting reports on the role of ADSC-EVs in tumor progression, some studies suggest that they can promote migration and proliferation of human breast cancer cells by activating the Wnt/β-catenin signaling pathway [60]. Conversely, other studies indicate that ADSC-EVs may act as tumor suppressors. For example, prostate cancer growth was notably inhibited in hormonal mice after treatment with ADSC-EVs [61]. In ovarian cancer, researchers discovered that human omental adipose-derived mesenchymal stem cell (HO-ADSC) potentiates ovarian cancer cell proliferation, migration, and invasion via the exosome-mediated FOXM1 signaling pathway, as demonstrated in co-culture and mechanistic studies. It was also speculated that HO-ADSC exosomes may facilitate ovarian cancer growth and metastasis by being secreted into ascites. Experiments in which ovarian cancer cell lines were treated with ascites from HGSOC patients showed enhanced cell proliferation, migration, and invasion, partially verifying the hypothesis. This finding offers a novel possible explanation for the clinical phenomenon that EOC patients frequently present with ascites and often spread to the greater omental visceral adipose tissue [62].

Angiogenesis

Tumor tissues exhibit highly vascularized characteristics, with the formation of new blood vessels being a crucial step in tumor growth and metastasis. As angiogenesis progresses, there is an escalation in the nutrient supply to the tumor tissues, leading to an accelerated rate of tumor cell division and proliferation. Excessive angiogenic activity can also promote the infiltration and distant metastasis of solid tumors [63]. During these processes, the upregulation of vascular endothelial growth factor (VEGF) expression serves as a primary influencing factor, facilitating rapid angiogenesis and promoting tumor growth [64]. VEGF exerts its specific effects on vascular endothelial cells by inducing proliferation, migration, and lumen formation, while also increasing vascular permeability [65]. EVs promote VEGF expression in endothelial cells. Feng et al. reported that EVs derived from breast cancer cells promote sustained activation of VEGF in endothelial cells, thereby facilitating tumor angiogenesis [66]. Similarly, Liu et al. elucidated that exosomal miR-21 can raise VEGF levels in recipient cells and induce angiogenesis and malignant transformation in human bronchial epithelial cells [67]. In ovarian cancer, researchers isolated exosomes derived from OVACAR-3 cells and treated endothelial cells with these exosomes. The results indicated that exosomes extracted from ovarian cancer cells upregulated the expression of VEGF in endothelial cells and promoted its secretion, thereby accelerating endothelial cell proliferation and migration [68].

Exosomes containing miRNAs secreted by ovarian cancer cells can be picked up by recipient cells and play an important role in tumor angiogenesis to promote tumor growth and metastasis. The exosome miR-205 secreted by ovarian cancer cells promotes metastasis by inducing angiogenesis in vivo and in vitro via the PTEN/AKT pathway, positioning it as a potential therapeutic target for ovarian cancer [69]. Furthermore, another study has identified sEV miR-141-3p, secreted by epithelial ovarian cancer cells, as an important mediator of intercellular communication and may upregulate VEGFR-2 expression in endothelial cells. Also, sEV miR-141-3p promoted endothelial cell migration and angiogenesis through activating JAK/STAT3 and NF-κB signaling pathways [70]. In addition, soluble epithelial cadherin (sE-cadherin) on the surface of exosomes can also regulate tumor angiogenesis and has similar VEGF efficiency. sE-cadherin is highly expressed in malignant ascites of ovarian cancer patients, triggering angiogenesis and promoting tumor progression through β-catenin and activation of NF-κB signaling cascade [71].

There have been inconsistent reports regarding the effects of EVs from MSCs on tumor angiogenesis, possibly due to variations in the types of MSCs from which the EVs originate. Exosomes derived from bone marrow mesenchymal stem cells were found to inhibit the secretion and expression of VEGF in breast cancer cells, thus suppressing angiogenesis [72]. Conversely, Liu et al. demonstrated that exosomes from human exfoliated deciduous teeth stem cells exerted inhibitory effects on tumor progression through angiogenesis suppression [73]. Recent research highlights a beneficial role of MSC-derived EVs in ovarian cancer. These EVs facilitate the delivery of miR-424, a miRNA implicated in suppressing tumor invasion and migration [74], thereby downregulating VEGF expression. Consequently, they inhibit the proliferation, migration, and tube formation of human umbilical vein endothelial cells, further restraining ovarian cancer angiogenesis and metastasis [75].

Anti-angiogenic drugs hold value in the frontline treatment, platinum-sensitive recurrence, and platinum-resistant recurrence of ovarian cancer. However, clinical trials such as GOG-218 and ICON-7 have demonstrated that while bevacizumab therapy shows some efficacy in ovarian cancer, it falls short of ideal outcomes, with a median progression-free survival extension of only about 3 months [76, 77]. Therefore, the quest for new and viable anti-angiogenic targets holds significant research value for ovarian cancer. EVs can mediate ovarian cancer metastasis by influencing angiogenesis, and EVs derived from stem cells can suppress tumor growth by inhibiting angiogenesis. This discovery offers a fresh perspective and new possibilities for tumor treatment and metastasis research, potentially paving the way for developments in clinical therapy. Further research in this area is anticipated.

Immune regulation

Tumor immune escape refers to the phenomenon whereby tumor cells evade recognition and attack by the host immune system through various mechanisms, allowing them to survive and proliferate in the body [78]. It is a crucial factor in the development of cancer and resistance to treatment. The mechanisms by which tumor cells undergo immune escape can be categorized into intrinsic and extrinsic factors. On one hand, tumor cells avoid immune recognition and clearance by downregulating MHC molecules, suppressing tumor-specific antigens, and employing other strategies. On the other hand, an immunosuppressive microenvironment is established. EVs can assist tumor cells in immune escape, thereby promoting the growth and metastasis of ovarian cancer.

EVs can promote tumor immune escape by inhibiting the function of T cells. Kelleher et al. reported that EVs in ovarian cancer ascites can suppress the activity of T cells in the ascites. This inhibition may be induced by phosphatidylserine (PS) on the surface of EVs, blocking T cell receptor signaling [79]. Another study elucidated that sEV transport arginase-1 from tumor cells to antigen-presenting cells in secondary lymphoid organs, leading to the suppression of antigen-specific T-cell proliferation and activation. This establishes an immunosuppressive microenvironment, dampening anti-tumor immune responses and ultimately promoting ovarian cancer progression [80]. TAMs are prone to polarize into the immunosuppressive M2-like subtype, initiating an immunosuppressive microenvironment through the secretion of EVs. NEAT1, a long non-coding RNA, has been reported as an oncogene in various malignancies and exhibits oncogenic properties in ovarian cancer as well [81]. Studies have shown that NEAT1 is highly expressed in EVs derived from M2-TAMs. Further mechanistic studies revealed that NEAT1 upregulates the expression of ZEB1 and PD-L1 through miR-101-3p, promoting CD8+ T cell apoptosis [82].

Th17 cells, a subset of CD4+ T cells, are pro-inflammatory Th cells that secrete cytokines such as IL-17 to mediate pro-inflammatory and pro-rejection responses. Regulatory T cells (Tregs), another subset of CD4+ T cells, play a crucial role in mediating peripheral immune tolerance, exerting immunosuppressive effects, and are dubbed the “accomplices” of tumor immune escape [83]. Tregs can inhibit the inflammatory response induced by Th17 cells and functionally counterbalance Th17 cells. An imbalance between Tregs and Th17 cells promotes the progression of EOC. The researchers found that M2 macrophages altered the Treg/Th17 balance when cocultured with T cells owing to release of exosomes. Further molecular mechanistic studies have shown that TAM-derived exosomes transport miRNAs targeting STAT3 to T cells and regulate the polarization of T cell subpopulations, leading to an imbalance between Treg and Th17 cells, creating an immunosuppressive microenvironment, which promotes the progression and metastasis of EOC [84].

As one of the most promising targets in the field of tumor immunotherapy, CD47 plays a key role in the self-recognition of the immune system, and tumors frequently take advantage of CD47 overexpression to achieve immune escape [85]. CD47 was found to be expressed on exosomes and is a key regulator of macrophage immune evasion during ovarian cancer progression. Inhibiting the secretion and uptake of exosomes can enhance the phagocytosis of cancer cells by M1 macrophages, weaken immune escape capabilities, and thus inhibit peritoneal dissemination. Targeting exosomal CD47 is speculated to be beneficial for the treatment of ovarian cancer. However, researchers have only conducted in vitro phagocytosis experiments using M1 macrophages, indicating the need for further investigation into the effects of exosomal CD47 on M2 macrophages [86].

The above studies indicate that EVs are involved in immune escape and metastasis of ovarian cancer cells. However, Luo et al. recently reported that exosomes derived from expanded natural killer cells can activate NK cells from the immunosuppressive microenvironment, reversing immune suppression and enhancing anti-ovarian cancer effects [87]. Therefore, despite facing significant challenges, the potential of targeting EVs in ovarian cancer immunotherapy should not be overlooked as more immunological features of EVs are revealed.

EMT

Epithelial-mesenchymal transition (EMT) is the process by which epithelial cells lose their epithelial phenotype and transform into cells with more mesenchymal characteristics. In this process, epithelial cells lose cell polarity and cell adhesion, and gain migration and invasiveness [88]. In recent years, EMT has been considered a necessary initial step in tumor cell invasion and metastasis, and thus has been intensively studied. Increasing evidence suggests that EVs carry functional molecular cargo, coordinating the EMT process in different cancers.

Ascites-derived exosomes (ADEs) play an important role in the progression of ovarian cancer, and ADEs promote ovarian cancer metastasis not only in vitro but also in vivo. By Bioinformatics analysis, it was found that miR-6780b-5p might be an important miRNA to promote ovarian cancer metastasis in ADEs, and the correlation between miR-6780b-5p and tumor metastasis was verified in ascites of ovarian cancer patients. To further investigate the function of miR-6780b-5p in EMT, researchers assessed tumor cell migration and EMT markers after regulating miR-6780b-5p expression with agomir or antagomir transfection. It was discovered that ADEs promote ovarian cancer metastasis by transferring miR-6780b-5p into ovarian cancer cells to facilitate EMT [89].

EVs can suppress the EMT in ovarian cancer cells. Many studies have elucidated the pro-tumorigenic effects of EVs derived from CAFs. For instance, CAFs-derived EVs carrying nucleic acid messages and proteins can promote EMT progression in colorectal cancer, as well as proliferation and metastasis in breast cancer [90]. Interestingly, Chen et al. co-cultured OVCA cells with EVs derived from CAFs and found that EMT in ovarian cancer cells was inhibited. And after using the exosome secretion inhibitor GW4869, the motility and invasiveness of OVCA cells were greatly enhanced. Further studies have shown that CAFs-derived exosomes are transferred between CAFs and OVCA cells, hinder EMT in tumor cells, and deliver circIFNGR2 and inhibit malignant progression of OVCA through the circIFNGR2/miR-378/ST5 axis [91]. Table 1 provides a comprehensive summary of the mechanisms by which EVs derived from various cell sources contribute to OC metastasis.

Table 1 Extracellular vesicles mediate ovarian cancer metastasis

EV source	EV type	EV cargo	Mechanism	Function	Refs	
Serum of EOC patients	Exosome	LRP1	Via p-ERK/MMP2/MMP9 pathway	Promote migration and invasion	Zhou W et al.	
M2 macrophages	Exosome	miR-221-3p	Target CDKN1B	Promote migration and invasion	Li X et al.	
OC cell lines	EV	miR-106a-5p	Target KLF6	Promote proliferation, invasion and migration	Zheng Y et al.	
TWEAK-stimulated macrophages	Exosome	miR-7	Inhibit the EGFR/AKT/ERK1/2 pathway	Inhibit invasion	Hu Y et al.	
OC cell lines	EV	circATP2B4	Via miR-532-3p/SREBF1/PI3Kα/AKT axis	Promote M2 Macrophage Polarization	Wang F et al.	
OC cell lines	EV	miR-181c-5p	Via KAT2B/HOXA10 axis and activate the JAK1/STAT3 pathway	Promote M2 Macrophage Polarization	Yang S et al.	
OC cell lines	Exosome	miR-141	Activate the YAP1/GROα/CXCR pathway	Form tumor-promoting stromal niche	Mo Y et al.	
OC cell lines	EV	miR-630	Inhibit KLF6 and activate NF-κB	Promote activation of CAFs	Cui Y et al.	
Ascites of OC patients and OC cell lines	EV	LncRNA SPOCD1-AS	Interact with G3BP1	Remodel mesothelial cells	Wang C et al.	
OC cell lines	Exosome	ANXA2	Via PI3K/AKT/mTOR pathway	Regulate epithelial-mesenchymal plasticity of peritoneal mesothelial cells	Gao L et al.	
OC cell lines	Exosome	circPUM1	Up-regulate NF-κB and MMP2	Promote MMT of peritoneal mesothelial cells	Guan X et al.	
OC cell lines	Exosome	miR-99a-5p	Increase fibronectin and vitronectin expression	Regulate peritoneal mesothelial cells	Yoshimura A et al.	
OC cell lines	Exosome	ETS1	Via integrin αvβ5/AKT/Sp1 pathway	Regulate peritoneal mesothelial cells	Li H et al.	
Omental CAFs	Exosome	miR-29c-3p	Target MMP2	Suppress OC cells invasion	Han Q et al.	
OC cell lines	Exosome	miR-205	Via PTEN-AKT pathway	Induce angiogenesis	He L et al.	
OC cell lines	sEV	miR-141-3p	Activate the JAK/STAT3 and NF-κB pathways	Promote endothelial cell angiogenesis	Masoumi-Dehghi S et al.	
OC cell lines	Exosome	E-cadherin	Activate the β-catenin and NF-κB pathway	Promote tumor angiogenesis	Tang MKS et al.	
MSCs	EV	miR-424	Down-regulate MYB	Inhibit angiogenesis	Li P et al.	
OC cell lines	EV	Phosphatidyl- serine	Arrest the T-cell signaling cascade	Inhibit T-cell function	Kelleher RJ Jr et al.	
OC cell lines	sEV	Arginase-1	Suppress T-cell responses	Mitigate anti-tumor immune responses	Czystowska-Kuzmicz M et al.	
M2-polarized TAMs	EV	NEAT1	Via miR-101-3p/ZEB1/PD-L1 axis	Promote CD8 + T cells apoptosis	Yin L et al.	
TAMs	Exosome	miR-29a-3p, miR-21-5p	Target STAT3	Induce a Treg/Th17 cell imbalance	Zhou J et al.	
CAFs	Exosome	circ IFNGR2	Via miR-378/ST5 axis	Inhibit EMT of OC cells	Chen X et al.	
OC, ovarian cancer; TAM, tumor-associated macrophages; CAF, tumor-associated fibroblast; MSC, mesenchymal stem cell; sEV, small extracellular vesicle; EMT, epithelial-mesenchymal transition; MMT, mesothelial-mesenchymal transition; ADE, ascites-derived exosome

In summary, EVs enhance ovarian cancer cells’ migratory and invasive abilities, facilitating their distant metastasis via peritoneal fluid, vasculature, and lymphatic pathways. At metastatic sites, EVs actively remodel stromal and immune cells within the microenvironment, fostering cancer cell adhesion, colonization, and proliferation, thereby expediting the metastatic process (Fig. 3).

Fig. 3 The composition of EVs and their roles in ovarian cancer metastasis. The surface of EVs is composed of a phospholipid bilayer adorned with a variety of membrane proteins, including transmembrane proteins, transporters, antigen-presenting proteins, and receptors. Within these EVs are various bioactive cargos, such as lipids, proteins, DNA, and a range of RNA molecules, both coding and non-coding, like lncRNA, circRNA, and miRNA, all of which are essential for intercellular communication. The transfer of these EV components is crucial in the metastatic process of ovarian cancer, where they enhance the dissemination potential of primary tumor cells, support the formation of PMN, and orchestrate multiple pathophysiological processes such as immune regulation, angiogenesis, and EMT

Over the past few years, research on EVs has surged exponentially, including significant contributions in the field of ovarian cancer. Technological advancements, particularly in the methods of EV isolation and analysis, have enabled deeper investigations into their biogenesis, surface markers, and internal composition. Furthermore, interdisciplinary collaborations among fields such as cell biology, molecular biology, biomedical engineering, and clinical medicine have provided strong momentum for advancing EV research [92].

Investigation of the molecular mechanisms by which EVs drive tumor metastasis is essential for advancing from laboratory research to clinical application. Preclinical investigations have validated the crucial role of EVs as mediators of intercellular communication in tumor progression. A thorough examination of the role of EVs in ovarian cancer metastasis provides novel insights into the assessment and prevention of tumor spread. As potential biomarkers, EVs could facilitate the early detection of metastasis or serve as tools for prognostic evaluation [93, 94]. Moreover, the diverse roles of EVs in the tumor microenvironment lay the groundwork for the development of targeted therapies, where disrupting EV biogenesis, release, and uptake may offer a novel approach to limiting ovarian cancer metastasis.

However, the complexity and heterogeneity of EVs present significant challenges in studying their involvement in ovarian cancer metastasis. EVs released from different cell types under varying physiological and pathological conditions exhibit substantial differences in both quantity and cargo composition [95]. This heterogeneity complicates the analysis of EV cargo, which is typically explored using transcriptomics, proteomics, and metabolomics to elucidate their role in cancer. However, single-omics approaches are limited in their capacity to fully capture the multi-dimension information among RNA, proteins, and metabolites, highlighting the importance of integrative multi-omics research for a comprehensive understanding of EV function and application. Compared to colorectal, prostate and breast cancers, ovarian cancer remains underexplored in multi-omics studies of EVs, leading to an incomplete understanding of their involvement in ovarian cancer progression and highlighting the need for more extensive and in-depth research [96–98].

Additionally, the heterogeneity of EVs has driven a growing interest in single-vesicle analysis. Recently, He R. et al. developed an innovative sEV heterogeneity tracking algorithm, SEVtras, capable of specifically capturing sEVs within single-cell sequencing data and analyzing the secretion activity of different cell types. This method offers an efficient approach for analyzing sEV secretion patterns at the single-cell level, bridging sEV biology with single-cell transcriptomics, and advancing the high-throughput tracking of sEV heterogeneity [99]. These technological advancements are expected to provide critical insights into the heterogeneity and biological functions of EVs, aiding in the precise elucidation of their roles in cancer development and progression.

While research on EVs in ovarian cancer remains in its nascent stages, the future directions of this field are becoming clearer. Advanced multi-omics approaches and bioinformatics techniques are expected to elucidate the heterogeneity of EVs, identifying distinct subpopulations and their molecular signatures from various cellular origins. These findings are indispensable for deepening our comprehension of the role of EVs in cancer metastasis and for establishing the foundation for future clinical translation.

What are the advancements and future directions of EVs in ovarian cancer drug resistance?

The overall survival rate for ovarian cancer is low, partly due to resistance to drugs such as cisplatin. Paclitaxel combined with platinum-based chemotherapy regimen is the first line of treatment for patients with advanced ovarian cancer after initial tumor cytoreduction. Although most of the patients are sensitive to platinum, they will be treated with multiple chemotherapy regimens due to recurrence, and will go from platinum-sensitive to platinum-resistant, and the survival outcome of platinum-resistant EOC is very poor [100]. Currently, new treatments for ovarian cancer resistance are in clinical trials, mainly including: Anti-angiogenic therapy, immunotherapy targeting PD-1/PD-L1, poly-ADP ribose polymerase inhibitors (PARPi) Olaparib, cell-cycle targeting CHK1/2 or WEE-1 modulators, epigenetic modulators such as next-generation hypomethylating agent guadecitabine [101–106]. Despite the promise of these approaches, some clinical trials have yielded negative results, underscoring the urgent need for additional therapeutic strategies for drug-resistant ovarian cancer.

Emerging research has highlighted the indispensable role of extracellular vesicles (EVs) in regulating tumor drug resistance. EVs not only mediate drug resistance mechanisms but also hold potential as drug delivery vehicles in cancer therapy (Table 2). Therefore, in-depth studies of EV-mediated tumor drug resistance contribute to the systematic revelation of the molecular mechanisms of drug resistance in ovarian cancer, and correspondingly, understanding the current status of EVs in the study of drug-resistant treatment of ovarian cancer can provide valuable insights for guiding the direction of future research on the clinical translation of EVs.

Table 2 Extracellular vesicles regulate ovarian cancer drug resistance

EV source	EV type	EV cargo	Mechanism	Function	Refs	
OC cell lines	Exosome	miR-1246	Via Cav1/p-gp/M2-type macrophage axis	Confer chemoresistance	Kanlikilicer P et al.	
OC cell lines	Exosome	miR-429	Target CASR via NF-κB	Confer chemoresistance	Li T et al.	
OC cell lines	Exosome	miR-21-3p	Target NAV3	Increase resistance to cisplatin	Pink RC et al.	
OC cell lines	Exosome	miR-21-5p	Target PDHA1	Inhibit chemosensitivity	Zhuang L et al.	
OC cell lines	Exosome	pGSN	Interact with HIF1α	Enhance chemoresistance	Asare-Werehene M et al.	
OC cell lines	sEV	pGSN	Regulate GSH	Enhance chemoresistance	Asare-Werehene M et al.	
Macrophages	Exosome	miR-223	Via PTEN-PI3K/AKT pathway	Elicit a chemoresistant phenotype	Zhu X et al.	
TAMs	EV	GATA3	Up-regulate the CD24/Siglec-10 axis	Enhance chemoresistance	Chen C et al.	
CAFs	Exosome	miR-98-5p	Down-regulate CDKN1A	Promote cisplatin resistance	Guo H et al.	
OC cell lines	Exosome	miR497, TP	Use exosome-liposome hybrid nanoparticles	Overcome chemoresistance	Li L et al.	
Mature bovine milk	Exosome	Cisplatin	Evade the endosome trapping	Enhance delivery of cisplatin	Zhou G et al.	
MSCs	EV	miR-18a-5p	Target NACC1 and activate the AKT/mTOR pathway	Promote cisplatin sensitivity	Wang X et al.	
hUCMSCs	Exosome	miR-146a	Via LAMC2-mediated PI3K/Akt axis	Promote docetaxel and taxane sensitivity	Qiu L et al.	
pGSN, plasma gelsolin; GSH, glutathione; TP, triptolide; UC, umbilical cord; hUCMSC, human umbilical cord mesenchymal stem cell; Ex-pGSN, exosome-transported pGSN.

Mediate drug resistance

Tumor cell-derived exosomes are involved in drug resistance by transporting drug resistance-associated nucleic acids such as microRNA and mRNA. miR-1246 is a circulating non-coding RNA in a variety of tumors, and a clinical study found that circulating miR-1246 may be a clinical diagnostic biomarker for HGSOC [107]. Researchers observed high expression of miR-1246 was expressed in OC exosomes, and the expression of Cav1, a direct target of exosomal miR-1246, was negatively correlated with the expression of multi drug resistance protein. Moreover, the genetic material in exosomes was taken up by pro-tumorigenic cells infiltrated in the tumor microenvironment; therefore, the release of large amounts of miR-1246 into the tumor microenvironment via exosomes may facilitate chemoresistance in OC patients. This study provides new possibilities for the clinical application of exosomes, on the one hand, exosomal miR-1246 may be able to be used as a serum biomarker to predict chemoresistance, and on the other hand, to overcome chemoresistance in OC patients through exosomal miR-1246. However, the mechanism by which exosomal miR-1246 mediates chemoresistance has not yet been fully elucidated in this study [108]. Exosomal miR-429 released by SKOV3 cells enhances cisplatin resistance in recipient cells in vitro and in vivo via CASR/STAT3 after uptake by recipient cells, and A2780 cells co-cultured with SKOV3 pretreated with miR-429 antagomir showed sensitivity to cisplatin. This study confirms that the cisplatin resistance is produced by horizontal transfer of exosomal miR-429 [109]. EVs secreted by drug-resistant ovarian cancer cells increase resistance in sensitive cells. A study found that exosomes released by drug-resistant CP70 cells increase resistance in A2780 cells [110]. Another study isolated cisplatin-resistant SKOV3 cell-derived exosomes to treat SKOV3 cells and found that sensitization of SKOV3 cells to DDP was inhibited by exosomal miR-21-5p [111]. Apart from directly delivering drug resistance-associated miRNAs, exosomes can also regulate epigenetic factors by enriching and delivering transcripts. DNA methylation is an important expression of epigenetic modifications, and DNA Methyltransferase 1 (DNMT1) is a key enzyme responsible for the precise replication and maintenance of DNA methylation patterns [112]. The relative content of DNMT1 was significantly high in exosomes derived from ovarian cancer cell lines. In vitro and in vivo experiments revealed that endogenous DNMT1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\text{t}\text{r}\text{a}\text{n}\text{s}\text{c}\text{r}\text{i}\text{p}\text{t}\text{s}$$\end{document}are highly specifically packaged into exosomes that are released into the extracellular milieu, thereby promoting DNMT1 expression in host cells. The resulting high expression of DNMT1 promotes cisplatin resistance in ovarian cancer cells through epigenetic alterations, and resistance is markedly suppressed in the presence of the exosome secretion inhibitor GW4869 [113].

Tumor-derived exosomes can also transmit drug resistance from cell to cell by carrying drug resistance-associated proteins, enzymes, and more. Plasma gelsolin (pGSN), a secreted isoform of GSN, is highly secreted in chemoresistant OVCA cells and is secreted and transported via exosomes. In patients with HGSOC, pGSN expression was significantly associated with poor chemotherapy responsiveness and shortened OS, making pGSN a poor prognostic marker [114]. Exo-pGSN upregulates pGSN expression in chemoresistant OVCA cells in an autocrine manner and confers cisplatin resistance in other chemoresistant OVCA cells [115].λAnother study reported an immunomodulatory role of sEV-pGSN in ovarian cancer chemoresistance. Under chemosensitive conditions, sEV-pGSN secretion is low, CD8+ T-cell function was optimal, and T-cell secretion of IFNγ was increased, which resulted in a reduction in the production of intracellular glutathione and sensitized chemosensitive cells to cisplatin-induced apoptosis. In contrast, in chemoresistance conditions, ovarian cancer cells secrete increased sEV-pGSN, which induces apoptosis in CD8+ T cells [116]. Cleft lip and palate transmembrane protein 1-like (CLPTM1L) is present in EVs of tumor culture supernatants and in patient sera, with levels increasing after chemotherapy. After treatment with ovarian cancer resistant cell line medium, cisplatin killing in sensitive cells was reduced, and treatment with 102-5 anti-CLPTM1L or exosome production inhibitor DMA restored cisplatin sensitivity. Also, tumor cell killing of carboplatin was reduced in EVs-treated ovarian cancer cells, and pretreatment of EVs with anti-CLPTM1L weakened carboplatin resistance and significantly enhanced killing. This confirmed that the exosome CLPTM1L from cisplatin-resistant ovarian cancer cells was able to transmit cisplatin resistance in drug-sensitive parental cells [117].

In addition, extracellular vesicles secreted by fibroblasts and immune-related cells in the tumor microenvironment also play an important role in ovarian cancer resistance. TAM derived exosomes can promote resistance in recipient cells by delivering microRNAs. miR-223 increase cisplatin resistance in gastric cancer by regulating the cell cycle and is a promising biomarker in recurrent ovarian cancer [118, 119]. Elevated levels of miR-223 were detected in serum exosomes of patients with recurrent EOC. The high levels of miR-223 observed in primary tumor homogenates may be due to exosomal transfer of miR-223 from surrounding TAMs rather than to high miR-223 expression in cancer cells. Metastatic TAM exosomal miR-223 is able to directly target PTEN and is involved in regulating EOC resistance. However, inhibiting miR-223 expression did not completely resist the promotion of drug resistance by TAM derived exosomes, and the specific reasons need to be further explored [120]. GATA3 encapsulated by TAM-derived EVs promotes chemoresistance in ovarian cancer by upregulating the CD24/ siglece − 10 axis. TAM-derived EVs releases large amounts of GATA3, which plays an important role in immunomodulation as a transcription factor that regulates T cell differentiation and development.GATA3 upregulates CD24 in OC cells, which binds to Siglecl-10 molecules on macrophages and reduces phagocytosis of the cells, thereby accelerating the role of CD24 in immune escape and chemotherapy resistance [121]. CAFs promote cisplatin resistance in OC cells by transferring exosomal miR-98-5p. Nude mouse xenograft tumor experiments showed that cancer-associated fibroblast-derived exosomal microRNA-98-5p downregulated CDKN1A in nude mice. Then CDKN1A, the key cell cycle regulatory protein, promotes cisplatin resistance in ovarian cancer after its downregulation [122].

EVs are associated with the bystander effects, a phenomenon that allows stress cells to communicate with their neighbors, leading to a variety of effects such as DNA damage. It has been shown that chemotherapeutic treatment of ovarian tumor cells leads to the release of EVs, which affects the phenotype of neighboring tumor cells. In the cisplatin-induced stress response, the release of EVs promotes the exchange of stressed cells and neighboring naive cells, and when these EVs are taken up by bystander ovarian cancer cells, they are able to induce enhanced invasiveness and drug resistance [123].

Platinum resistance in ovarian cancer stems from reduced intracellular platinum uptake, increased platinum efflux, intracellular platinum inactivation, and enhanced DNA damage repair [124]. EVs can promote intracellular chemotherapeutic agent efflux, particularly under hypoxic conditions, leading to increased cisplatin excretion by ovarian cancer cells [125]. Moreover, EV-mediated drug efflux is modulated by other factors. O-GlcNAcylation, an important post-translational protein modification, was found to be down-regulated to promote exosome secretion. This increased exosome-mediated cisplatin efflux from ovarian cancer cells, leading to chemoresistance. Blocking the transfer of EVs between cells may be a way to address chemoresistance in ovarian cancer, but more in vivo and in vitro experiments are needed in the future [126].

The exploration of EVs in drug resistance in ovarian cancer is still at an early stage. The above studies have initially revealed the mechanism of EVs inducing chemoresistance in ovarian cancer, but they have focused more on the influence of EVs on the cellular drug resistance phenotype. Many of these pathways and intricate mechanisms involved in this phenomenon remain incompletely understood, and no systematic findings have been formed yet, leaving more research to be conducted in the future.

Enhance drug delivery and reverse drug resistance

Effective targeted drug delivery is currently a bottleneck in disease treatment. Over the past decades, various nanocarrier drug delivery systems have been developed and synthesized in order to improve the therapeutic efficacy of drugs [127]. Tumor-targeted drug delivery systems can specifically reach tumor tissues, tumor cells and organelles to improve therapeutic efficacy [128]. Among nanoparticles, liposomes have been the most successful carriers, with the highest number of clinical approvals. However, the clinical application of lipid nanocarriers has experienced many difficulties, such as low bioavailability, easy removal from the bloodstream or stimulation of innate immune responses [129]. Recently, EVs, nature’s lipid nanoparticles, have received great attention as drug delivery vehicles. EVs offer high stability, low immunogenicity, excellent biocompatibility, and efficient penetration through biofilms, making them promising alternatives to lipid nanoparticles for drug delivery [130]. Moreover, there is a growing interest in nucleic acid drugs. EVs as potential carriers to stabilize nucleic acids and overcome their instability and cell permeability barriers offer new possibilities for the development and application of nucleic acid drugs.

EVs and liposomes each possess unique advantages and limitations. Recently, membrane fusion technology has been utilized to fuse EVs with liposomes to form hybrid particles, which have the advantages of both EVs and liposomes, and show great potential for targeted cancer therapy [131]. Overexpression of miR497 overcomes OC chemoresistance by inhibiting the mTOR pathway, and tretinoin (TP) also has a killing effect on cisplatin-resistant cells partly by inhibiting the mTOR pathway. Combined application of miR497 and TP was envisioned to further overcome OC chemoresistance by cooperatively inhibiting the mTOR signaling pathway. However, the low transcriptional efficiency and unstable chemically nature of mir497, as well as the severe systemic toxicity and weak aqueous solubility of TP, were obstacles to this concept. To overcome these challenges, researchers constructed hybrid nanoparticles formed by fusion of tumor exosomes and cRGD-modified liposomes to co-deliver miR497 and TP, named miR497/TP-HENPs. The miR497/TP-HENPs were able to encapsulate drugs and protect nucleic acids efficiently and release TP and miR497 stably and continuously, successfully overcoming OC resistance. Such nanoparticle encapsulation provides a new solution and translational strategy to overcome OC cisplatin resistance [132]. In another study, modification of exosomes by RGD was found to improve tumor targeting. RGD-modified exosomes efficiently targeted delivery of miR-484, improved vascular normalization, increased chemosensitivity of ovarian cancer, and prolonged the survival time of homozygous mice after chemotherapy, offering a new avenue for improving chemosensitivity in ovarian cancer.

Cisplatin resistance is primarily mediated by two mechanisms: reduced transport dependent on the plasma membrane transporter hCTR1 and sequestration within endosomes. Since the target of cisplatin is DNA in the nucleus, cisplatin isolated by endosomes will not be able to access the target [133]. Extracellular vesicles from milk show potential in drug delivery, milk exosomes can encapsulate cisplatin and transport the drug to cisplatin-resistant ovarian cancers, augmenting the anticancer effects of cisplatin [134]. By using inhibitors and knocking down key molecules, milk exosomes were found to deliver cisplatin mainly through clathrin-independent endocytosis and macropinocytosis, avoiding cisplatin capture by endosomes and enhancing the drug’s effect against ovarian cancer. However, it is not clear whether milk exosomes can effectively deliver other chemotherapeutic drugs and whether they can play a role in drug resistance in other cancers. As well as the study did not compare with other drug delivery systems such as liposomes. In addition, the safety of milk exosomes needs to be further verified before clinical application, particularly with regard to immune response [135].

MSC-derived EVs have emerged as key players in antitumor therapy [136]. In vitro and in vivo experiments revealed that hMSC-EVs enhanced sensitivity to cisplatin and inhibited the tumorigenic capacity of OC by transferring miR-18-5p [137]. Human umbilical cord is one of the sources of MSC and exhibits faster self-renewal compared to bone marrow-derived MSC [138]. Human umbilical cord MSCs release the exosome miR-146a, which reduces LAMC2 expression through the PI3K/Akt signaling pathway, thereby sensitizing OC cells to docetaxel and taxane [139]. Compared to RAW 264.7 macrophages, umbilical cord blood macrophages have the advantages of low immunogenicity and low toxicity. In contrast to peripheral blood macrophages, umbilical cord blood macrophages exhibit slower aging. It was demonstrated that M1 macrophage-derived exosomes reduced the IC50 of cisplatin in ovarian cancer and was more pronounced in drug-resistant cell lines, allowing M1 exosomes to be a potential new tool for delivering cisplatin. However, the lack of in vivo experiments, uncertainties regarding safety and antitumor effects in animals, and the need for further elucidation of the mechanism underlying resistance reversal underscore the necessity for additional research in this area [140].

In conclusion, drug resistance remains the greatest challenge in ovarian cancer treatment. The recent findings and research progress on the role of EVs in overcoming drug resistance in ovarian cancer are summarized and discussed, with an emphasis on their potential in clinical applications to combat chemotherapy resistance. This promising avenue may significantly enhance the prognosis of ovarian cancer patients. However, several challenges need to be addressed. Firstly, obtaining high-purity and high-yield EVs is an essential cornerstone for the clinical translation of EVs. Current isolation techniques have limitations, including low extraction efficiency and purity, as well as high time and economic costs, hindering the application of EVs in drug-resistant ovarian cancer treatment. Therefore, there is a need to develop new standardized isolation and purification strategies. Secondly, how to make EVs effective for drug loading and targeted delivery is also one of the technical challenges that require urgent solution. Currently, researchers have introduced genes, which fuse homing proteins and exosomal transmembrane proteins, into parental cells by means of genetic engineering, enabling specific proteins to be displayed on the surface of exosomal membranes to improve targeting. Yet targeting molecules for cancer cells are still lacking [141]. In addition, most of the current studies are conducted in vitro, requiring more rigorous in vivo experiments to validate biosafety as well as therapeutic efficacy. Clinical application studies are also scarce, insufficiently in-depth and of poor reliability. Future studies must address the aforementioned issues, with the prospect of broader application of EVs in overcoming chemoresistance in ovarian cancer being particularly promising.

Conclusions and future perspectives

To conclude, research on EVs has made significant strides in understanding OC metastasis and resistance mechanisms. Additionally, research on EVs has opened up numerous new avenues for the clinical treatment and management of cancer.

Firstly, EVs are widely present in various body fluids, offering unique advantages as an innovative liquid biopsy technique in vitro diagnostics. Currently, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) are the most commonly used in liquid biopsy [142]. While EVs cannot fully replace CTCs and ctDNA due to their lower DNA content and current technological limitations, their high stability and ease of collection provide distinct advantages. Recently, there has been a surge in in-depth studies on EVs as biomarkers, employing multi-omics and machine learning to identify EV biomarkers for disease diagnosis and prognosis. A multi-cohort, multi-stage study involving 2,141 patients found that EV-expressed GClnc1 could serve as a circulating biomarker for early detection and monitoring of gastric cancer progression [143]. Further studies revealed that circulating EV-derived lncRNA-GC1 could predict neoadjuvant chemotherapy response and exhibit earlier dynamic changes than traditional gastrointestinal biomarkers [144]. Another multicenter cohort study found that a panel of 13 miRNAs in plasma can be used for early detection of pancreatic ductal adenocarcinoma, demonstrating very high diagnostic performance [145]. In the context of OC, several studies have been initiated. Li et al. have developed a serum sEV miRNA model for the identification of EOC, which has shown superior performance compared to CA125 in distinguishing stage I EOC patients from those with benign conditions [146]. Another study has also developed a combination of serum sEV proteins (CA125, HE4, and C5a) for the early diagnosis of EOC [147].

Secondly, EVs are emerging as innovative tools in cancer therapeutics. On one hand, EVs can serve as effective delivery systems for targeted cancer therapy, enhancing drug efficacy and specificity while reducing side effects. On the other hand, EVs play a role in cancer immunotherapy. A recent study reported that exosomes derived from CAR-NK cells can enhance clinical benefits in the treatment of HER2-positive breast cancer brain metastases [148]. Numerous clinical trials are underway. For instance, a phase I trial at Anderson Cancer Center (NCT03608631) uses MSC-Exos containing siRNA targeting oncogenic KrasG12D mutation for pancreatic cancer treatment. Another phase II trial (NCT01159288) employs dendritic cell-derived exosomes as vaccines combined with cyclophosphamide therapy for unresectable non-small cell lung cancer, with results yet to be published.

In summary, while significant advancements have been achieved in the research of EVs in OC, numerous mechanisms and challenges remain to be elucidated. Future research should focus on: thoroughly investigating the biological roles of EVs in OC; developing more accurate and dependable EV biomarkers for the early diagnosis and prognosis of OC; and exploring innovative EV-based therapeutic strategies for OC. Additionally, reinforcing clinical validation studies of EVs as potential therapeutic targets will provide more robust evidence for clinical applications. With ongoing technological advancements, deeper research, and proactive clinical validation, EVs are anticipated to drive further breakthroughs and innovations in the diagnosis and treatment of OC, ultimately paving the way for more personalized and precision oncology.

Acknowledgements

Figures in the paper were drawn using Figdraw platform(www.fgdraw. com).

Author contributions

WD and TC were responsible for the conception and design of the study. WD drafted and edited the manuscript. TC and JWZ reviewed and made revisions to the manuscript. All authors have read and approved the final version of the manuscript.

Funding

The study was supported by National Natural Science Foundation of China (Grant No. 82173220).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Ethical approval

Not applicable.

Abbreviations

OC ovarian cancer

EVs extracellular vesicles

EOC epithelial ovarian cancers

PARPis poly ADP-ribose polymerase inhibitors

LRP1 lipoprotein receptor-related protein 1

TAMs tumor-associated macrophages

CDKN1B cyclin-dependent kinase inhibitor 1B

TNF tumor necrosis factor

TMs TWEAK-stimulated macrophages

PMN pre-metastatic niche

M1 classically activated macrophages

M2 alternatively activated macrophages

HPMCs human peritoneal mesothelial cells

MMT mesothelial-mesenchymal transition

ANXA2 annexin A2

CAF carcinoma-associated fibroblast

NFs normal fibroblasts

ADSCs adipose-derived stem cells

MSCs mesenchymal stem cells

HO-ADSC human omental Adipose-derived mesenchymal stem cell

VEGF vascular endothelial growth factor

sE-cadherin soluble epithelial calmodulin

PS phosphatidylserine

Tregs regulatory T cells

EMT epithelial-mesenchymal transition

ADEs ascites-derived exosomes

DNMT1 DNA Methyltransferase 1

pGSN plasma gelsolin

CLPTM1L cleft lip and palate transmembrane protein 1-like

TP tretinoin

CTC circulating tumor cells

ctDNA circulating tumor DNA

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Bray F Laversanne M Sung H Ferlay J Siegel RL Soerjomataram I Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2024 74 3 229 63 10.3322/caac.21834 38572751
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.38572751 10.3322/caac.21834
2. Webb PM Jordan SJ Global epidemiology of epithelial ovarian cancer Nat Rev Clin Oncol 2024 21 5 389 400 10.1038/s41571-024-00881-3 38548868
Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389–400.38548868 10.1038/s41571-024-00881-3
3. Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 3 209 49 10.3322/caac.21660 33538338
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.33538338 10.3322/caac.21660
4. Crosbie EJ Kitson SJ McAlpine JN Mukhopadhyay A Powell ME Singh N Endometrial cancer Lancet 2022 399 10333 1412 28 10.1016/S0140-6736(22)00323-3 35397864
Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.35397864 10.1016/S0140-6736(22)00323-3
5. Armstrong DK Alvarez RD Bakkum-Gamez JN Barroilhet L Behbakht K Berchuck A Ovarian Cancer, Version 2.2020, NCCN Clinical Practice guidelines in Oncology J Natl Compr Canc Netw 2021 19 2 191 226 10.6004/jnccn.2021.0007 33545690
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(2):191–226.33545690 10.6004/jnccn.2021.0007
6. Schoutrop E Moyano-Galceran L Lheureux S Mattsson J Lehti K Dahlstrand H Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment Semin Cancer Biol 2022 86 Pt 3 207 23 10.1016/j.semcancer.2022.03.027 35395389
Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86(Pt 3):207–23.35395389 10.1016/j.semcancer.2022.03.027
7. Moore K Colombo N Scambia G Kim BG Oaknin A Friedlander M Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer N Engl J Med 2018 379 26 2495 505 10.1056/NEJMoa1810858 30345884
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505.30345884 10.1056/NEJMoa1810858
8. Banerjee S Moore KN Colombo N Scambia G Kim BG Oaknin A Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 2021 22 12 1721 31 10.1016/S1470-2045(21)00531-3 34715071
Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721–31.34715071 10.1016/S1470-2045(21)00531-3
9. González-Martín A Pothuri B Vergote I DePont Christensen R Graybill W Mirza MR Niraparib in patients with newly diagnosed Advanced Ovarian Cancer N Engl J Med 2019 381 25 2391 402 10.1056/NEJMoa1910962 31562799
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–402.31562799 10.1056/NEJMoa1910962
10. Ray-Coquard I Pautier P Pignata S Pérol D González-Martín A Berger R Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer N Engl J Med 2019 381 25 2416 28 10.1056/NEJMoa1911361 31851799
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–28.31851799 10.1056/NEJMoa1911361
11. Hardesty MM Krivak TC Wright GS Hamilton E Fleming EL Belotte J OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab Gynecol Oncol 2022 166 2 219 29 10.1016/j.ygyno.2022.05.020 35690498
Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166(2):219–29.35690498 10.1016/j.ygyno.2022.05.020
12. Moore KN Angelergues A Konecny GE García Y Banerjee S Lorusso D Mirvetuximab Soravtansine in FRα-Positive, platinum-resistant ovarian Cancer N Engl J Med 2023 389 23 2162 74 10.1056/NEJMoa2309169 38055253
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FRα-Positive, platinum-resistant ovarian Cancer. N Engl J Med. 2023;389(23):2162–74.38055253 10.1056/NEJMoa2309169
13. Harter P Trillsch F Okamoto A Reuss A Kim J-W Rubio-Pérez MJ Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial J Clin Oncol 2023 41 17suppl LBA5506 LBA 10.1200/JCO.2023.41.17_suppl.LBA5506
Harter P, Trillsch F, Okamoto A, Reuss A, Kim J-W, Rubio-Pérez MJ, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol. 2023;41(17suppl):LBA5506–LBA.10.1200/JCO.2023.41.17_suppl.LBA5506
14. Swisher EM Lin KK Oza AM Scott CL Giordano H Sun J Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial Lancet Oncol 2017 18 1 75 87 10.1016/S1470-2045(16)30559-9 27908594
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.27908594 10.1016/S1470-2045(16)30559-9
15. Armstrong DK Alvarez RD Backes FJ Bakkum-Gamez JN Barroilhet L Behbakht K NCCN Guidelines® insights: ovarian Cancer, Version 3.2022 J Natl Compr Canc Netw 2022 20 9 972 80 10.6004/jnccn.2022.0047 36075393
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN Guidelines® insights: ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022;20(9):972–80.36075393 10.6004/jnccn.2022.0047
16. Feng JL Dixon-Suen SC Jordan SJ Webb PM Statin use and survival among women with ovarian cancer: an Australian national data-linkage study Br J Cancer 2021 125 5 766 71 10.1038/s41416-021-01460-4 34135470
Feng JL, Dixon-Suen SC, Jordan SJ, Webb PM. Statin use and survival among women with ovarian cancer: an Australian national data-linkage study. Br J Cancer. 2021;125(5):766–71.34135470 10.1038/s41416-021-01460-4
17. Ma L Li Y Peng J Wu D Zhao X Cui Y Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration Cell Res 2015 25 1 24 38 10.1038/cr.2014.135 25342562
Ma L, Li Y, Peng J, Wu D, Zhao X, Cui Y, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015;25(1):24–38.25342562 10.1038/cr.2014.135
18. Welsh JA Goberdhan DCI O’Driscoll L Buzas EI Blenkiron C Bussolati B Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches J Extracell Vesicles 2024 13 2 e12404 10.1002/jev2.12404 38326288
Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404.38326288 10.1002/jev2.12404
19. Couch Y Buzàs EI Di Vizio D Gho YS Harrison P Hill AF A brief history of nearly EV-erything - the rise and rise of extracellular vesicles J Extracell Vesicles 2021 10 14 e12144 10.1002/jev2.12144 34919343
Couch Y, Buzàs EI, Di Vizio D, Gho YS, Harrison P, Hill AF, et al. A brief history of nearly EV-erything - the rise and rise of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12144.34919343 10.1002/jev2.12144
20. O’Brien K Breyne K Ughetto S Laurent LC Breakefield XO RNA delivery by extracellular vesicles in mammalian cells and its applications Nat Rev Mol Cell Biol 2020 21 10 585 606 10.1038/s41580-020-0251-y 32457507
O’Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10):585–606.32457507 10.1038/s41580-020-0251-y
21. Hade MD Suire CN Mossell J Suo Z Extracellular vesicles: emerging frontiers in wound healing Med Res Rev 2022 42 6 2102 25 10.1002/med.21918 35757979
Hade MD, Suire CN, Mossell J, Suo Z. Extracellular vesicles: emerging frontiers in wound healing. Med Res Rev. 2022;42(6):2102–25.35757979 10.1002/med.21918
22. Xu R Rai A Chen M Suwakulsiri W Greening DW Simpson RJ Extracellular vesicles in cancer - implications for future improvements in cancer care Nat Rev Clin Oncol 2018 15 10 617 38 10.1038/s41571-018-0036-9 29795272
Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15(10):617–38.29795272 10.1038/s41571-018-0036-9
23. Yu W Hurley J Roberts D Chakrabortty SK Enderle D Noerholm M Exosome-based liquid biopsies in cancer: opportunities and challenges Ann Oncol 2021 32 4 466 77 10.1016/j.annonc.2021.01.074 33548389
Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466–77.33548389 10.1016/j.annonc.2021.01.074
24. Kipps E Tan DS Kaye SB Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research Nat Rev Cancer 2013 13 4 273 82 10.1038/nrc3432 23426401
Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273–82.23426401 10.1038/nrc3432
25. Rauch JN Luna G Guzman E Audouard M Challis C Sibih YE LRP1 is a master regulator of tau uptake and spread Nature 2020 580 7803 381 5 10.1038/s41586-020-2156-5 32296178
Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580(7803):381–5.32296178 10.1038/s41586-020-2156-5
26. Zhou W Ma J Zhao H Wang Q Guo X Chen L Serum exosomes from epithelial ovarian Cancer patients contain LRP1, which promotes the Migration of Epithelial Ovarian Cancer Cell Mol Cell Proteom 2023 22 4 100520 10.1016/j.mcpro.2023.100520
Zhou W, Ma J, Zhao H, Wang Q, Guo X, Chen L, et al. Serum exosomes from epithelial ovarian Cancer patients contain LRP1, which promotes the Migration of Epithelial Ovarian Cancer Cell. Mol Cell Proteom. 2023;22(4):100520.10.1016/j.mcpro.2023.100520
27. Wang X Zhao X Wang K Wu L Duan T Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro Cancer Sci 2013 104 4 516 23 10.1111/cas.12110 23347208
Wang X, Zhao X, Wang K, Wu L, Duan T. Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro. Cancer Sci. 2013;104(4):516–23.23347208 10.1111/cas.12110
28. Li X Tang M Exosomes released from M2 macrophages transfer mir-221-3p contributed to EOC progression through targeting CDKN1B Cancer Med 2020 9 16 5976 88 10.1002/cam4.3252 32590883
Li X, Tang M. Exosomes released from M2 macrophages transfer mir-221-3p contributed to EOC progression through targeting CDKN1B. Cancer Med. 2020;9(16):5976–88.32590883 10.1002/cam4.3252
29. Zheng Y Zhu K Wang G miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6 Clin Exp Metastasis 2022 39 4 603 21 10.1007/s10585-022-10165-8 35449340
Zheng Y, Zhu K, Wang G. miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6. Clin Exp Metastasis. 2022;39(4):603–21.35449340 10.1007/s10585-022-10165-8
30. Li J Hu C Chao H Zhang Y Li Y Hou J Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma J Cell Mol Med 2021 25 19 9183 98 10.1111/jcmm.16801 34469038
Li J, Hu C, Chao H, Zhang Y, Li Y, Hou J, et al. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma. J Cell Mol Med. 2021;25(19):9183–98.34469038 10.1111/jcmm.16801
31. Hu J Xie C Xu S Pu Q Liu H Yang L Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma PLoS ONE 2023 18 5 e0286017 10.1371/journal.pone.0286017 37228062
Hu J, Xie C, Xu S, Pu Q, Liu H, Yang L, et al. Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma. PLoS ONE. 2023;18(5):e0286017.37228062 10.1371/journal.pone.0286017
32. Xing L Tang X Wu K Huang X Yi Y Huan J LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p Aging 2020 13 1 424 36 10.18632/aging.202148 33290256
Xing L, Tang X, Wu K, Huang X, Yi Y, Huan J. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p. Aging. 2020;13(1):424–36.33290256 10.18632/aging.202148
33. Shen X Wang C Zhu H Wang Y Wang X Cheng X Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells J Ovarian Res 2021 14 1 38 10.1186/s13048-021-00776-2 33627162
Shen X, Wang C, Zhu H, Wang Y, Wang X, Cheng X, et al. Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells. J Ovarian Res. 2021;14(1):38.33627162 10.1186/s13048-021-00776-2
34. Kaduka Y Takeda K Nakayama M Kinoshita K Yagita H Okumura K TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage Biochem Biophys Res Commun 2005 331 2 384 90 10.1016/j.bbrc.2005.03.176 15850771
Kaduka Y, Takeda K, Nakayama M, Kinoshita K, Yagita H, Okumura K. TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage. Biochem Biophys Res Commun. 2005;331(2):384–90.15850771 10.1016/j.bbrc.2005.03.176
35. Hu Y Li D Wu A Qiu X Di W Huang L TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA Cancer Lett 2017 393 60 7 10.1016/j.canlet.2017.02.009 28216373
Hu Y, Li D, Wu A, Qiu X, Di W, Huang L, et al. TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. Cancer Lett. 2017;393:60–7.28216373 10.1016/j.canlet.2017.02.009
36. Liu Y Cao X Characteristics and significance of the pre-metastatic niche Cancer Cell 2016 30 5 668 81 10.1016/j.ccell.2016.09.011 27846389
Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668–81.27846389 10.1016/j.ccell.2016.09.011
37. Xiang X Wang J Lu D Xu X Targeting tumor-associated macrophages to synergize tumor immunotherapy Signal Transduct Target Ther 2021 6 1 75 10.1038/s41392-021-00484-9 33619259
Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75.33619259 10.1038/s41392-021-00484-9
38. Chen D Zhang X Li Z Zhu B Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages Theranostics 2021 11 3 1016 30 10.7150/thno.51777 33391518
Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11(3):1016–30.33391518 10.7150/thno.51777
39. Wang F Niu Y Chen K Yuan X Qin Y Zheng F Extracellular vesicle-packaged circATP2B4 mediates M2 macrophage polarization via miR-532-3p/SREBF1 Axis to promote epithelial ovarian Cancer metastasis Cancer Immunol Res 2023 11 2 199 216 10.1158/2326-6066.CIR-22-0410 36512324
Wang F, Niu Y, Chen K, Yuan X, Qin Y, Zheng F, et al. Extracellular vesicle-packaged circATP2B4 mediates M2 macrophage polarization via miR-532-3p/SREBF1 Axis to promote epithelial ovarian Cancer metastasis. Cancer Immunol Res. 2023;11(2):199–216.36512324 10.1158/2326-6066.CIR-22-0410
40. Yang S Zhao H Xiao W Shao L Zhao C Sun P Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis J Gene Med 2022 24 10 e3446 10.1002/jgm.3446 36027869
Yang S, Zhao H, Xiao W, Shao L, Zhao C, Sun P. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis. J Gene Med. 2022;24(10):e3446.36027869 10.1002/jgm.3446
41. Mo Y Leung LL Mak CSL Wang X Chan WS Hui LMN Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis Mol Cancer 2023 22 1 4 10.1186/s12943-022-01703-9 36624516
Mo Y, Leung LL, Mak CSL, Wang X, Chan WS, Hui LMN, et al. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer. 2023;22(1):4.36624516 10.1186/s12943-022-01703-9
42. Cui Y Wang D Xie M Tumor-derived extracellular vesicles promote activation of Carcinoma-Associated fibroblasts and facilitate Invasion and Metastasis of Ovarian Cancer by carrying miR-630 Front Cell Dev Biol 2021 9 652322 10.3389/fcell.2021.652322 34277601
Cui Y, Wang D, Xie M. Tumor-derived extracellular vesicles promote activation of Carcinoma-Associated fibroblasts and facilitate Invasion and Metastasis of Ovarian Cancer by carrying miR-630. Front Cell Dev Biol. 2021;9:652322.34277601 10.3389/fcell.2021.652322
43. Pradeep S Kim SW Wu SY Nishimura M Chaluvally-Raghavan P Miyake T Hematogenous metastasis of ovarian cancer: rethinking mode of spread Cancer Cell 2014 26 1 77 91 10.1016/j.ccr.2014.05.002 25026212
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26(1):77–91.25026212 10.1016/j.ccr.2014.05.002
44. Peinado H Zhang H Matei IR Costa-Silva B Hoshino A Rodrigues G Pre-metastatic niches: organ-specific homes for metastases Nat Rev Cancer 2017 17 5 302 17 10.1038/nrc.2017.6 28303905
Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17(5):302–17.28303905 10.1038/nrc.2017.6
45. Yokoi A Yoshioka Y Yamamoto Y Ishikawa M Ikeda SI Kato T Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer Nat Commun 2017 8 14470 10.1038/ncomms14470 28262727
Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun. 2017;8:14470.28262727 10.1038/ncomms14470
46. Li J, Guo T. Role of peritoneal mesothelial cells in the progression of peritoneal metastases. Cancers (Basel). 2022;14(12).
47. Wang C Wang J Shen X Li M Yue Y Cheng X LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1 J Exp Clin Cancer Res 2021 40 1 101 10.1186/s13046-021-01899-6 33726799
Wang C, Wang J, Shen X, Li M, Yue Y, Cheng X, et al. LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1. J Exp Clin Cancer Res. 2021;40(1):101.33726799 10.1186/s13046-021-01899-6
48. Gao L Nie X Gou R Hu Y Dong H Li X Exosomal ANXA2 derived from ovarian cancer cells regulates epithelial-mesenchymal plasticity of human peritoneal mesothelial cells J Cell Mol Med 2021 25 23 10916 29 10.1111/jcmm.16983 34725902
Gao L, Nie X, Gou R, Hu Y, Dong H, Li X, et al. Exosomal ANXA2 derived from ovarian cancer cells regulates epithelial-mesenchymal plasticity of human peritoneal mesothelial cells. J Cell Mol Med. 2021;25(23):10916–29.34725902 10.1111/jcmm.16983
49. Guan X Zong ZH Liu Y Chen S Wang LL Zhao Y circPUM1 promotes tumorigenesis and progression of ovarian Cancer by sponging mir-615-5p and miR-6753-5p Mol Ther Nucleic Acids 2019 18 882 92 10.1016/j.omtn.2019.09.032 31751911
Guan X, Zong ZH, Liu Y, Chen S, Wang LL, Zhao Y. circPUM1 promotes tumorigenesis and progression of ovarian Cancer by sponging mir-615-5p and miR-6753-5p. Mol Ther Nucleic Acids. 2019;18:882–92.31751911 10.1016/j.omtn.2019.09.032
50. Li X Tang M Zhu Q Wang X Lin Y Wang X The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration Cell Oncol (Dordr) 2020 43 2 263 77 10.1007/s13402-019-00486-4 32080801
Li X, Tang M, Zhu Q, Wang X, Lin Y, Wang X. The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration. Cell Oncol (Dordr). 2020;43(2):263–77.32080801 10.1007/s13402-019-00486-4
51. Nakamura K Sawada K Kinose Y Yoshimura A Toda A Nakatsuka E Exosomes promote Ovarian Cancer Cell Invasion through transfer of CD44 to peritoneal mesothelial cells Mol Cancer Res 2017 15 1 78 92 10.1158/1541-7786.MCR-16-0191 27758876
Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote Ovarian Cancer Cell Invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78–92.27758876 10.1158/1541-7786.MCR-16-0191
52. Yoshimura A Sawada K Nakamura K Kinose Y Nakatsuka E Kobayashi M Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells BMC Cancer 2018 18 1 1065 10.1186/s12885-018-4974-5 30396333
Yoshimura A, Sawada K, Nakamura K, Kinose Y, Nakatsuka E, Kobayashi M, et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065.30396333 10.1186/s12885-018-4974-5
53. Nieman KM Kenny HA Penicka CV Ladanyi A Buell-Gutbrod R Zillhardt MR Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat Med 2011 17 11 1498 503 10.1038/nm.2492 22037646
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503.22037646 10.1038/nm.2492
54. Lee W Ko SY Mohamed MS Kenny HA Lengyel E Naora H Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum J Exp Med 2019 216 1 176 94 10.1084/jem.20181170 30567719
Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176–94.30567719 10.1084/jem.20181170
55. Li H Zeng C Shu C Cao Y Shao W Zhang M Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer Cell Death Dis 2022 13 12 1028 10.1038/s41419-022-05472-7 36477408
Li H, Zeng C, Shu C, Cao Y, Shao W, Zhang M, et al. Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer. Cell Death Dis. 2022;13(12):1028.36477408 10.1038/s41419-022-05472-7
56. Hu JL Wang W Lan XL Zeng ZC Liang YS Yan YR CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer Mol Cancer 2019 18 1 91 10.1186/s12943-019-1019-x 31064356
Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91.31064356 10.1186/s12943-019-1019-x
57. Liu T Han C Wang S Fang P Ma Z Xu L Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy J Hematol Oncol 2019 12 1 86 10.1186/s13045-019-0770-1 31462327
Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86.31462327 10.1186/s13045-019-0770-1
58. Han Q Tan S Gong L Li G Wu Q Chen L Omental cancer-associated fibroblast-derived exosomes with low microRNA-29c-3p promote ovarian cancer peritoneal metastasis Cancer Sci 2023 114 5 1929 42 10.1111/cas.15726 36644823
Han Q, Tan S, Gong L, Li G, Wu Q, Chen L, et al. Omental cancer-associated fibroblast-derived exosomes with low microRNA-29c-3p promote ovarian cancer peritoneal metastasis. Cancer Sci. 2023;114(5):1929–42.36644823 10.1111/cas.15726
59. Zhang Y Dong W Wang J Cai J Wang Z Human omental adipose-derived mesenchymal stem cell-conditioned medium alters the proteomic profile of epithelial ovarian cancer cell lines in vitro Onco Targets Ther 2017 10 1655 63 10.2147/OTT.S129502 28360526
Zhang Y, Dong W, Wang J, Cai J, Wang Z. Human omental adipose-derived mesenchymal stem cell-conditioned medium alters the proteomic profile of epithelial ovarian cancer cell lines in vitro. Onco Targets Ther. 2017;10:1655–63.28360526 10.2147/OTT.S129502
60. Lin R Wang S Zhao RC Exosomes from human adipose-derived mesenchymal stem cells promote migration through wnt signaling pathway in a breast cancer cell model Mol Cell Biochem 2013 383 1–2 13 20 10.1007/s11010-013-1746-z 23812844
Lin R, Wang S, Zhao RC. Exosomes from human adipose-derived mesenchymal stem cells promote migration through wnt signaling pathway in a breast cancer cell model. Mol Cell Biochem. 2013;383(1–2):13–20.23812844 10.1007/s11010-013-1746-z
61. Takahara K Ii M Inamoto T Nakagawa T Ibuki N Yoshikawa Y microRNA-145 mediates the Inhibitory Effect of Adipose tissue-derived stromal cells on prostate Cancer Stem Cells Dev 2016 25 17 1290 8 10.1089/scd.2016.0093 27465939
Takahara K, Ii M, Inamoto T, Nakagawa T, Ibuki N, Yoshikawa Y, et al. microRNA-145 mediates the Inhibitory Effect of Adipose tissue-derived stromal cells on prostate Cancer. Stem Cells Dev. 2016;25(17):1290–8.27465939 10.1089/scd.2016.0093
62. Qu Q Liu L Cui Y Chen Y Wang Y Wang Y Exosomes from human omental adipose-derived mesenchymal stem cells secreted into Ascites promote peritoneal metastasis of epithelial ovarian Cancer Cells 2022 11 21 10.3390/cells11213392
Qu Q, Liu L, Cui Y, Chen Y, Wang Y, Wang Y. Exosomes from human omental adipose-derived mesenchymal stem cells secreted into Ascites promote peritoneal metastasis of epithelial ovarian Cancer. Cells. 2022;11:21.10.3390/cells11213392
63. Li S Xu HX Wu CT Wang WQ Jin W Gao HL Angiogenesis in pancreatic cancer: current research status and clinical implications Angiogenesis 2019 22 1 15 36 10.1007/s10456-018-9645-2 30168025
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15–36.30168025 10.1007/s10456-018-9645-2
64. Patel SA Nilsson MB Le X Cascone T Jain RK Heymach JV Molecular mechanisms and future implications of VEGF/VEGFR in Cancer Therapy Clin Cancer Res 2023 29 1 30 9 10.1158/1078-0432.CCR-22-1366 35969170
Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res. 2023;29(1):30–9.35969170 10.1158/1078-0432.CCR-22-1366
65. Apte RS Chen DS Ferrara N VEGF in Signaling and Disease: Beyond Discovery and Development Cell 2019 176 6 1248 64 10.1016/j.cell.2019.01.021 30849371
Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248–64.30849371 10.1016/j.cell.2019.01.021
66. Feng Q Zhang C Lum D Druso JE Blank B Wilson KF A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis Nat Commun 2017 8 14450 10.1038/ncomms14450 28205552
Feng Q, Zhang C, Lum D, Druso JE, Blank B, Wilson KF, et al. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017;8:14450.28205552 10.1038/ncomms14450
67. Liu Y Luo F Wang B Li H Xu Y Liu X STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells Cancer Lett 2016 370 1 125 35 10.1016/j.canlet.2015.10.011 26525579
Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X, et al. STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. Cancer Lett. 2016;370(1):125–35.26525579 10.1016/j.canlet.2015.10.011
68. Ghorbanian M Babashah S Ataei F The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells Excli j 2019 18 899 907 31645849
Ghorbanian M, Babashah S, Ataei F. The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells. Excli j. 2019;18:899–907.31645849
69. He L Zhu W Chen Q Yuan Y Wang Y Wang J Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis Theranostics 2019 9 26 8206 20 10.7150/thno.37455 31754391
He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang J, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 2019;9(26):8206–20.31754391 10.7150/thno.37455
70. Masoumi-Dehghi S Babashah S Sadeghizadeh M microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways J Cell Commun Signal 2020 14 2 233 44 10.1007/s12079-020-00548-5 32034654
Masoumi-Dehghi S, Babashah S, Sadeghizadeh M. microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways. J Cell Commun Signal. 2020;14(2):233–44.32034654 10.1007/s12079-020-00548-5
71. Tang MKS Yue PYK Ip PP Huang RL Lai HC Cheung ANY Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface Nat Commun 2018 9 1 2270 10.1038/s41467-018-04695-7 29891938
Tang MKS, Yue PYK, Ip PP, Huang RL, Lai HC, Cheung ANY, et al. Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nat Commun. 2018;9(1):2270.29891938 10.1038/s41467-018-04695-7
72. Pakravan K Babashah S Sadeghizadeh M Mowla SJ Mossahebi-Mohammadi M Ataei F MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells Cell Oncol (Dordr) 2017 40 5 457 70 10.1007/s13402-017-0335-7 28741069
Pakravan K, Babashah S, Sadeghizadeh M, Mowla SJ, Mossahebi-Mohammadi M, Ataei F, et al. MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells. Cell Oncol (Dordr). 2017;40(5):457–70.28741069 10.1007/s13402-017-0335-7
73. Liu P Zhang Q Mi J Wang S Xu Q Zhuang D Exosomes derived from stem cells of human deciduous exfoliated teeth inhibit angiogenesis in vivo and in vitro via the transfer of mir-100-5p and miR-1246 Stem Cell Res Ther 2022 13 1 89 10.1186/s13287-022-02764-9 35241153
Liu P, Zhang Q, Mi J, Wang S, Xu Q, Zhuang D, et al. Exosomes derived from stem cells of human deciduous exfoliated teeth inhibit angiogenesis in vivo and in vitro via the transfer of mir-100-5p and miR-1246. Stem Cell Res Ther. 2022;13(1):89.35241153 10.1186/s13287-022-02764-9
74. Li T Li Y Gan Y Tian R Wu Q Shu G Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23 Cell Cycle 2019 18 14 1601 18 10.1080/15384101.2019.1624112 31135262
Li T, Li Y, Gan Y, Tian R, Wu Q, Shu G, et al. Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23. Cell Cycle. 2019;18(14):1601–18.31135262 10.1080/15384101.2019.1624112
75. Li P Xin H Lu L Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB J Transl Med 2021 19 1 4 10.1186/s12967-020-02652-x 33407591
Li P, Xin H, Lu L. Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting MYB. J Transl Med. 2021;19(1):4.33407591 10.1186/s12967-020-02652-x
76. Tewari KS Burger RA Enserro D Norquist BM Swisher EM Brady MF Final overall survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer J Clin Oncol 2019 37 26 2317 28 10.1200/JCO.19.01009 31216226
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019;37(26):2317–28.31216226 10.1200/JCO.19.01009
77. Oza AM Cook AD Pfisterer J Embleton A Ledermann JA Pujade-Lauraine E Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Lancet Oncol 2015 16 8 928 36 10.1016/S1470-2045(15)00086-8 26115797
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.26115797 10.1016/S1470-2045(15)00086-8
78. Liu Y Wang Y Yang Y Weng L Wu Q Zhang J Emerging phagocytosis checkpoints in cancer immunotherapy Signal Transduct Target Ther 2023 8 1 104 10.1038/s41392-023-01365-z 36882399
Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104.36882399 10.1038/s41392-023-01365-z
79. Kelleher RJ Jr Balu-Iyer S Loyall J Sacca AJ Shenoy GN Peng P Extracellular vesicles Present in Human ovarian tumor microenvironments induce a phosphatidylserine-dependent arrest in the T-cell Signaling Cascade Cancer Immunol Res 2015 3 11 1269 78 10.1158/2326-6066.CIR-15-0086 26112921
Kelleher RJ Jr., Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, et al. Extracellular vesicles Present in Human ovarian tumor microenvironments induce a phosphatidylserine-dependent arrest in the T-cell Signaling Cascade. Cancer Immunol Res. 2015;3(11):1269–78.26112921 10.1158/2326-6066.CIR-15-0086
80. Czystowska-Kuzmicz M Sosnowska A Nowis D Ramji K Szajnik M Chlebowska-Tuz J Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma Nat Commun 2019 10 1 3000 10.1038/s41467-019-10979-3 31278254
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10(1):3000.31278254 10.1038/s41467-019-10979-3
81. Yin L Wang Y Long non-coding RNA NEAT1 facilitates the growth, migration, and invasion of ovarian cancer cells via the let-7 g/MEST/ATGL axis Cancer Cell Int 2021 21 1 437 10.1186/s12935-021-02018-3 34416900
Yin L, Wang Y. Long non-coding RNA NEAT1 facilitates the growth, migration, and invasion of ovarian cancer cells via the let-7 g/MEST/ATGL axis. Cancer Cell Int. 2021;21(1):437.34416900 10.1186/s12935-021-02018-3
82. Yin L Wang Y Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis Cancer Immunol Immunother 2023 72 3 743 58 10.1007/s00262-022-03305-2 36319716
Yin L, Wang Y. Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis. Cancer Immunol Immunother. 2023;72(3):743–58.36319716 10.1007/s00262-022-03305-2
83. Hinshaw DC Benavides GA Metge BJ Swain CA Kammerud SC Alsheikh HA Hedgehog signaling regulates Treg to Th17 Conversion through metabolic rewiring in breast Cancer Cancer Immunol Res 2023 11 5 687 702 10.1158/2326-6066.CIR-22-0426 37058110
Hinshaw DC, Benavides GA, Metge BJ, Swain CA, Kammerud SC, Alsheikh HA, et al. Hedgehog signaling regulates Treg to Th17 Conversion through metabolic rewiring in breast Cancer. Cancer Immunol Res. 2023;11(5):687–702.37058110 10.1158/2326-6066.CIR-22-0426
84. Zhou J Li X Wu X Zhang T Zhu Q Wang X Exosomes released from Tumor-Associated macrophages transfer miRNAs that induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer Cancer Immunol Res 2018 6 12 1578 92 10.1158/2326-6066.CIR-17-0479 30396909
Zhou J, Li X, Wu X, Zhang T, Zhu Q, Wang X, et al. Exosomes released from Tumor-Associated macrophages transfer miRNAs that induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Cancer Immunol Res. 2018;6(12):1578–92.30396909 10.1158/2326-6066.CIR-17-0479
85. Tang L Yin Y Cao Y Fu C Liu H Feng J Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based Cancer Immunotherapy Adv Mater 2023 35 35 e2303835 10.1002/adma.202303835 37384818
Tang L, Yin Y, Cao Y, Fu C, Liu H, Feng J, et al. Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based Cancer Immunotherapy. Adv Mater. 2023;35(35):e2303835.37384818 10.1002/adma.202303835
86. Shimizu A Sawada K Kobayashi M Yamamoto M Yagi T Kinose Y Exosomal CD47 plays an essential role in Immune Evasion in Ovarian Cancer Mol Cancer Res 2021 19 9 1583 95 10.1158/1541-7786.MCR-20-0956 34016744
Shimizu A, Sawada K, Kobayashi M, Yamamoto M, Yagi T, Kinose Y, et al. Exosomal CD47 plays an essential role in Immune Evasion in Ovarian Cancer. Mol Cancer Res. 2021;19(9):1583–95.34016744 10.1158/1541-7786.MCR-20-0956
87. Luo H Zhou Y Zhang J Zhang Y Long S Lin X NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions Front Immunol 2022 13 1087689 10.3389/fimmu.2022.1087689 36741396
Luo H, Zhou Y, Zhang J, Zhang Y, Long S, Lin X, et al. NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions. Front Immunol. 2022;13:1087689.36741396 10.3389/fimmu.2022.1087689
88. Lamouille S Xu J Derynck R Molecular mechanisms of epithelial-mesenchymal transition Nat Rev Mol Cell Biol 2014 15 3 178 96 10.1038/nrm3758 24556840
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.24556840 10.1038/nrm3758
89. Cai J Gong L Li G Guo J Yi X Wang Z Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p Cell Death Dis 2021 12 2 210 10.1038/s41419-021-03490-5 33627627
Cai J, Gong L, Li G, Guo J, Yi X, Wang Z. Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis. 2021;12(2):210.33627627 10.1038/s41419-021-03490-5
90. Li C Teixeira AF Zhu HJ Ten Dijke P Cancer associated-fibroblast-derived exosomes in cancer progression Mol Cancer 2021 20 1 154 10.1186/s12943-021-01463-y 34852849
Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20(1):154.34852849 10.1186/s12943-021-01463-y
91. Chen X Ren X Zhou EJ Bian Y Exosome-transmitted circIFNGR2 modulates ovarian Cancer metastasis via miR-378/ST5 Axis Mol Cell Biol 2023 43 1 22 42 10.1080/10985549.2022.2160605 36720469
Chen X, Ren X, Zhou EJ, Bian Y. Exosome-transmitted circIFNGR2 modulates ovarian Cancer metastasis via miR-378/ST5 Axis. Mol Cell Biol. 2023;43(1):22–42.36720469 10.1080/10985549.2022.2160605
92. Shin H Choi BH Shim O Kim J Park Y Cho SK Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers Nat Commun 2023 14 1 1644 10.1038/s41467-023-37403-1 36964142
Shin H, Choi BH, Shim O, Kim J, Park Y, Cho SK, et al. Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers. Nat Commun. 2023;14(1):1644.36964142 10.1038/s41467-023-37403-1
93. de Miguel-Perez D Ak M Mamindla P Russo A Zenkin S Ak N Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC J Experimental Clin Cancer Research: CR 2024 43 1 81 10.1186/s13046-024-02997-x
de Miguel-Perez D, Ak M, Mamindla P, Russo A, Zenkin S, Ak N, et al. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Experimental Clin Cancer Research: CR. 2024;43(1):81.10.1186/s13046-024-02997-x
94. Ricklefs FL Wollmann K Salviano-Silva A Drexler R Maire CL Kaul MG Circulating extracellular vesicles as biomarker for diagnosis, prognosis, and monitoring in glioblastoma patients Neuro Oncol 2024 26 7 1280 91 10.1093/neuonc/noae068 38567448
Ricklefs FL, Wollmann K, Salviano-Silva A, Drexler R, Maire CL, Kaul MG, et al. Circulating extracellular vesicles as biomarker for diagnosis, prognosis, and monitoring in glioblastoma patients. Neuro Oncol. 2024;26(7):1280–91.38567448 10.1093/neuonc/noae068
95. Burbidge K Zwikelmaier V Cook B Long MM Balva B Lonigro M Cargo and cell-specific differences in extracellular vesicle populations identified by multiplexed immunofluorescent analysis J Extracell Vesicles 2020 9 1 1789326 10.1080/20013078.2020.1789326 32944176
Burbidge K, Zwikelmaier V, Cook B, Long MM, Balva B, Lonigro M, et al. Cargo and cell-specific differences in extracellular vesicle populations identified by multiplexed immunofluorescent analysis. J Extracell Vesicles. 2020;9(1):1789326.32944176 10.1080/20013078.2020.1789326
96. Eylem CC Yilmaz M Derkus B Nemutlu E Camci CB Yilmaz E Untargeted multi-omic analysis of colorectal cancer-specific exosomes reveals joint pathways of colorectal cancer in both clinical samples and cell culture Cancer Lett 2020 469 186 94 10.1016/j.canlet.2019.10.038 31669517
Eylem CC, Yilmaz M, Derkus B, Nemutlu E, Camci CB, Yilmaz E, et al. Untargeted multi-omic analysis of colorectal cancer-specific exosomes reveals joint pathways of colorectal cancer in both clinical samples and cell culture. Cancer Lett. 2020;469:186–94.31669517 10.1016/j.canlet.2019.10.038
97. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N et al. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024;42(7).
98. Shen L, Huang H, Wei Z, Chen W, Li J, Yao Y et al. Integrated transcriptomics, proteomics, and functional analysis to characterize the tissue-specific small extracellular vesicle network of breast cancer. MedComm (2020). 2023;4(6):e433.
99. He R Zhu J Ji P Zhao F SEVtras delineates small extracellular vesicles at droplet resolution from single-cell transcriptomes Nat Methods 2024 21 2 259 66 10.1038/s41592-023-02117-1 38049696
He R, Zhu J, Ji P, Zhao F. SEVtras delineates small extracellular vesicles at droplet resolution from single-cell transcriptomes. Nat Methods. 2024;21(2):259–66.38049696 10.1038/s41592-023-02117-1
100. Ghoneum A Almousa S Warren B Abdulfattah AY Shu J Abouelfadl H Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer Semin Cancer Biol 2021 77 83 98 10.1016/j.semcancer.2020.12.024 33476723
Ghoneum A, Almousa S, Warren B, Abdulfattah AY, Shu J, Abouelfadl H, et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:83–98.33476723 10.1016/j.semcancer.2020.12.024
101. Liu JF Herold C Gray KP Penson RT Horowitz N Konstantinopoulos PA Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: a phase 2 clinical trial JAMA Oncol 2019 5 12 1731 8 10.1001/jamaoncol.2019.3343 31600397
Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731–8.31600397 10.1001/jamaoncol.2019.3343
102. Lan CY Wang Y Xiong Y Li JD Shen JX Li YF Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study Lancet Oncol 2018 19 9 1239 46 10.1016/S1470-2045(18)30349-8 30082170
Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 2018;19(9):1239–46.30082170 10.1016/S1470-2045(18)30349-8
103. Biagi JJ Oza AM Chalchal HI Grimshaw R Ellard SL Lee U A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials Group Study Ann Oncol 2011 22 2 335 40 10.1093/annonc/mdq357 20705911
Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials Group Study. Ann Oncol. 2011;22(2):335–40.20705911 10.1093/annonc/mdq357
104. Lee JM Nair J Zimmer A Lipkowitz S Annunziata CM Merino MJ Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study Lancet Oncol 2018 19 2 207 15 10.1016/S1470-2045(18)30009-3 29361470
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018;19(2):207–15.29361470 10.1016/S1470-2045(18)30009-3
105. Matulonis UA Oza AM Secord AA Roman LD Blagden SP Banerjee SN Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): results of a randomized phase II study J Clin Oncol 2016 34 15suppl 5547 10.1200/JCO.2016.34.15_suppl.5547
Matulonis UA, Oza AM, Secord AA, Roman LD, Blagden SP, Banerjee SN, et al. Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): results of a randomized phase II study. J Clin Oncol. 2016;34(15suppl):5547.10.1200/JCO.2016.34.15_suppl.5547
106. Lheureux S Cabanero M Cristea MC Mantia-Smaldone G Olawaiye A Ellard S A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: a trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia J Clin Oncol 2019 37 15suppl 5518 10.1200/JCO.2019.37.15_suppl.5518
Lheureux S, Cabanero M, Cristea MC, Mantia-Smaldone G, Olawaiye A, Ellard S, et al. A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: a trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. J Clin Oncol. 2019;37(15suppl):5518.10.1200/JCO.2019.37.15_suppl.5518
107. Todeschini P Salviato E Paracchini L Ferracin M Petrillo M Zanotti L Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts Cancer Lett 2017 388 320 7 10.1016/j.canlet.2016.12.017 28017893
Todeschini P, Salviato E, Paracchini L, Ferracin M, Petrillo M, Zanotti L, et al. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts. Cancer Lett. 2017;388:320–7.28017893 10.1016/j.canlet.2016.12.017
108. Kanlikilicer P Bayraktar R Denizli M Rashed MH Ivan C Aslan B Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer EBioMedicine 2018 38 100 12 10.1016/j.ebiom.2018.11.004 30487062
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38:100–12.30487062 10.1016/j.ebiom.2018.11.004
109. Li T Lin L Liu Q Gao W Chen L Sha C Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer Am J Cancer Res 2021 11 5 2124 41 34094673
Li T, Lin L, Liu Q, Gao W, Chen L, Sha C, et al. Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer. Am J Cancer Res. 2021;11(5):2124–41.34094673
110. Pink RC Samuel P Massa D Caley DP Brooks SA Carter DR The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells Gynecol Oncol 2015 137 1 143 51 10.1016/j.ygyno.2014.12.042 25579119
Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143–51.25579119 10.1016/j.ygyno.2014.12.042
111. Zhuang L Zhang B Liu X Lin L Wang L Hong Z Exosomal mir-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1 Cell Biol Int 2021 45 10 2140 9 10.1002/cbin.11671 34288231
Zhuang L, Zhang B, Liu X, Lin L, Wang L, Hong Z, et al. Exosomal mir-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Cell Biol Int. 2021;45(10):2140–9.34288231 10.1002/cbin.11671
112. Wu C Liu Y Liu W Zou T Lu S Zhu C NNMT-DNMT1 Axis is essential for maintaining Cancer Cell sensitivity to oxidative phosphorylation inhibition Adv Sci (Weinh) 2022 10 1 e2202642 10.1002/advs.202202642 36382559
Wu C, Liu Y, Liu W, Zou T, Lu S, Zhu C, et al. NNMT-DNMT1 Axis is essential for maintaining Cancer Cell sensitivity to oxidative phosphorylation inhibition. Adv Sci (Weinh). 2022;10(1):e2202642.36382559 10.1002/advs.202202642
113. Cao YL Zhuang T Xing BH Li N Li Q Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer Cell Biochem Funct 2017 35 6 296 303 10.1002/cbf.3276 28791708
Cao YL, Zhuang T, Xing BH, Li N, Li Q. Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer. Cell Biochem Funct. 2017;35(6):296–303.28791708 10.1002/cbf.3276
114. Asare-Werehene M Communal L Carmona E Le T Provencher D Mes-Masson AM Pre-operative circulating plasma Gelsolin predicts residual Disease and detects early stage ovarian Cancer Sci Rep 2019 9 1 13924 10.1038/s41598-019-50436-1 31558772
Asare-Werehene M, Communal L, Carmona E, Le T, Provencher D, Mes-Masson AM, et al. Pre-operative circulating plasma Gelsolin predicts residual Disease and detects early stage ovarian Cancer. Sci Rep. 2019;9(1):13924.31558772 10.1038/s41598-019-50436-1
115. Asare-Werehene M Nakka K Reunov A Chiu CT Lee WT Abedini MR The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance Oncogene 2020 39 7 1600 16 10.1038/s41388-019-1087-9 31700155
Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, et al. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 2020;39(7):1600–16.31700155 10.1038/s41388-019-1087-9
116. Asare-Werehene M Communal L Carmona E Han Y Song YS Burger D Plasma Gelsolin inhibits CD8(+) T-cell function and regulates glutathione production to Confer Chemoresistance in Ovarian Cancer Cancer Res 2020 80 18 3959 71 10.1158/0008-5472.CAN-20-0788 32641415
Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, et al. Plasma Gelsolin inhibits CD8(+) T-cell function and regulates glutathione production to Confer Chemoresistance in Ovarian Cancer. Cancer Res. 2020;80(18):3959–71.32641415 10.1158/0008-5472.CAN-20-0788
117. Parashar D Geethadevi A McAllister D Ebben J Peterson FC Jensen DR Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance NPJ Precis Oncol 2021 5 1 16 10.1038/s41698-021-00152-9 33654182
Parashar D, Geethadevi A, McAllister D, Ebben J, Peterson FC, Jensen DR, et al. Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance. NPJ Precis Oncol. 2021;5(1):16.33654182 10.1038/s41698-021-00152-9
118. Zhou X Jin W Jia H Yan J Zhang G MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7 J Exp Clin Cancer Res 2015 34 1 28 10.1186/s13046-015-0145-6 25888377
Zhou X, Jin W, Jia H, Yan J, Zhang G. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 2015;34(1):28.25888377 10.1186/s13046-015-0145-6
119. Laios A O’Toole S Flavin R Martin C Kelly L Ring M Potential role of miR-9 and miR-223 in recurrent ovarian cancer Mol Cancer 2008 7 35 10.1186/1476-4598-7-35 18442408
Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.18442408 10.1186/1476-4598-7-35
120. Zhu X Shen H Yin X Yang M Wei H Chen Q Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype J Exp Clin Cancer Res 2019 38 1 81 10.1186/s13046-019-1095-1 30770776
Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38(1):81.30770776 10.1186/s13046-019-1095-1
121. Chen C Zhang L Ruan Z GATA3 encapsulated by Tumor-Associated macrophage-derived extracellular vesicles promotes Immune escape and Chemotherapy Resistance of Ovarian Cancer cells by upregulating the CD24/Siglec-10 Axis Mol Pharm 2023 20 2 971 86 10.1021/acs.molpharmaceut.2c00557 36547230
Chen C, Zhang L, Ruan Z. GATA3 encapsulated by Tumor-Associated macrophage-derived extracellular vesicles promotes Immune escape and Chemotherapy Resistance of Ovarian Cancer cells by upregulating the CD24/Siglec-10 Axis. Mol Pharm. 2023;20(2):971–86.36547230 10.1021/acs.molpharmaceut.2c00557
122. Guo H Ha C Dong H Yang Z Ma Y Ding Y Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A Cancer Cell Int 2019 19 347 10.1186/s12935-019-1051-3 31889899
Guo H, Ha C, Dong H, Yang Z, Ma Y, Ding Y. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. 2019;19:347.31889899 10.1186/s12935-019-1051-3
123. Samuel P, Mulcahy LA, Furlong F, McCarthy HO, Brooks SA, Fabbri M et al. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells. Philos Trans R Soc Lond B Biol Sci. 2018;373(1737).
124. Galluzzi L Senovilla L Vitale I Michels J Martins I Kepp O Molecular mechanisms of cisplatin resistance Oncogene 2012 31 15 1869 83 10.1038/onc.2011.384 21892204
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.21892204 10.1038/onc.2011.384
125. Dorayappan KDP Wanner R Wallbillich JJ Saini U Zingarelli R Suarez AA Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins Oncogene 2018 37 28 3806 21 10.1038/s41388-018-0189-0 29636548
Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene. 2018;37(28):3806–21.29636548 10.1038/s41388-018-0189-0
126. Qian L Yang X Li S Zhao H Gao Y Zhao S Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer Cell Death Discov 2021 7 1 112 10.1038/s41420-021-00489-x 34001861
Qian L, Yang X, Li S, Zhao H, Gao Y, Zhao S, et al. Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. Cell Death Discov. 2021;7(1):112.34001861 10.1038/s41420-021-00489-x
127. Su C Liu Y Li R Wu W Fawcett JP Gu J Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems Adv Drug Deliv Rev 2019 143 97 114 10.1016/j.addr.2019.06.008 31255595
Su C, Liu Y, Li R, Wu W, Fawcett JP, Gu J. Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems. Adv Drug Deliv Rev. 2019;143:97–114.31255595 10.1016/j.addr.2019.06.008
128. Fan D Cao Y Cao M Wang Y Cao Y Gong T Nanomedicine in cancer therapy Signal Transduct Target Ther 2023 8 1 293 10.1038/s41392-023-01536-y 37544972
Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8(1):293.37544972 10.1038/s41392-023-01536-y
129. Zong Y Lin Y Wei T Cheng Q Lipid nanoparticle (LNP) enables mRNA delivery for Cancer Therapy Adv Mater 2023 35 51 e2303261 10.1002/adma.202303261 37196221
Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for Cancer Therapy. Adv Mater. 2023;35(51):e2303261.37196221 10.1002/adma.202303261
130. Tenchov R Sasso JM Wang X Liaw WS Chen CA Zhou QA ExosomesNature’s lipid nanoparticles, a rising star in Drug Delivery and Diagnostics ACS Nano 2022 16 11 17802 46 10.1021/acsnano.2c08774 36354238
Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. ExosomesNature’s lipid nanoparticles, a rising star in Drug Delivery and Diagnostics. ACS Nano. 2022;16(11):17802–46.36354238 10.1021/acsnano.2c08774
131. Zhang W Ngo L Tsao SC Liu D Wang Y Engineered Cancer-Derived Small Extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast Cancer ACS Appl Mater Interfaces 2023 15 13 16420 33 10.1021/acsami.2c22749 36961985
Zhang W, Ngo L, Tsao SC, Liu D, Wang Y. Engineered Cancer-Derived Small Extracellular vesicle-liposome hybrid delivery system for targeted treatment of breast Cancer. ACS Appl Mater Interfaces. 2023;15(13):16420–33.36961985 10.1021/acsami.2c22749
132. Li L He D Guo Q Zhang Z Ru D Wang L Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer J Nanobiotechnol 2022 20 1 50 10.1186/s12951-022-01264-5
Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20(1):50.10.1186/s12951-022-01264-5
133. Zhitomirsky B Assaraf YG Lysosomes as mediators of drug resistance in cancer Drug Resist Updat 2016 24 23 33 10.1016/j.drup.2015.11.004 26830313
Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 2016;24:23–33.26830313 10.1016/j.drup.2015.11.004
134. Somiya M Yoshioka Y Ochiya T Biocompatibility of highly purified bovine milk-derived extracellular vesicles J Extracell Vesicles 2018 7 1 1440132 10.1080/20013078.2018.1440132 29511463
Somiya M, Yoshioka Y, Ochiya T. Biocompatibility of highly purified bovine milk-derived extracellular vesicles. J Extracell Vesicles. 2018;7(1):1440132.29511463 10.1080/20013078.2018.1440132
135. Zhou G Gu Y Zhu Z Zhang H Liu W Xu B Exosome mediated cytosolic cisplatin delivery through clathrin-independent endocytosis and enhanced anti-cancer effect via avoiding endosome trapping in cisplatin-resistant ovarian Cancer Front Med (Lausanne) 2022 9 810761 10.3389/fmed.2022.810761 35592860
Zhou G, Gu Y, Zhu Z, Zhang H, Liu W, Xu B, et al. Exosome mediated cytosolic cisplatin delivery through clathrin-independent endocytosis and enhanced anti-cancer effect via avoiding endosome trapping in cisplatin-resistant ovarian Cancer. Front Med (Lausanne). 2022;9:810761.35592860 10.3389/fmed.2022.810761
136. Yuan Z Kolluri KK Gowers KH Janes SM TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy J Extracell Vesicles 2017 6 1 1265291 10.1080/20013078.2017.1265291 28326166
Yuan Z, Kolluri KK, Gowers KH, Janes SM. TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy. J Extracell Vesicles. 2017;6(1):1265291.28326166 10.1080/20013078.2017.1265291
137. Wang X Jiang L Liu Q miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance J Transl Med 2022 20 1 258 10.1186/s12967-022-03422-7 35672774
Wang X, Jiang L, Liu Q. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance. J Transl Med. 2022;20(1):258.35672774 10.1186/s12967-022-03422-7
138. Hoang DM Pham PT Bach TQ Ngo ATL Nguyen QT Phan TTK Stem cell-based therapy for human diseases Signal Transduct Target Ther 2022 7 1 272 10.1038/s41392-022-01134-4 35933430
Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.35933430 10.1038/s41392-022-01134-4
139. Qiu L Wang J Chen M Chen F Tu W Exosomal microRNA–146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2–mediated PI3K/Akt axis Int J Mol Med 2020 46 2 609 20 10.3892/ijmm.2020.4634 32626953
Qiu L, Wang J, Chen M, Chen F, Tu W. Exosomal microRNA–146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2–mediated PI3K/Akt axis. Int J Mol Med. 2020;46(2):609–20.32626953 10.3892/ijmm.2020.4634
140. Zhang X Liu L Tang M Li H Guo X Yang X The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells Drug Dev Ind Pharm 2020 46 7 1150 62 10.1080/03639045.2020.1776320 32482115
Zhang X, Liu L, Tang M, Li H, Guo X, Yang X. The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm. 2020;46(7):1150–62.32482115 10.1080/03639045.2020.1776320
141. Alvarez-Erviti L Seow Y Yin H Betts C Lakhal S Wood MJ Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 2011 29 4 341 5 10.1038/nbt.1807 21423189
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–5.21423189 10.1038/nbt.1807
142. Amato O Aftimos P Ignatiadis M Liquid biopsy accelerates precision medicine Ann Oncol 2023 34 4 333 5 10.1016/j.annonc.2023.02.004 36804455
Amato O, Aftimos P, Ignatiadis M. Liquid biopsy accelerates precision medicine. Ann Oncol. 2023;34(4):333–5.36804455 10.1016/j.annonc.2023.02.004
143. Guo X Peng Y Song Q Wei J Wang X Ru Y A Liquid Biopsy Signature for the early detection of gastric Cancer in patients Gastroenterology 2023 165 2 402 e1313 10.1053/j.gastro.2023.02.044 36894035
Guo X, Peng Y, Song Q, Wei J, Wang X, Ru Y, et al. A Liquid Biopsy Signature for the early detection of gastric Cancer in patients. Gastroenterology. 2023;165(2):402–e1313.36894035 10.1053/j.gastro.2023.02.044
144. Guo X Gao Y Song Q Wei J Wu J Dong J Early assessment of circulating exosomal lncRNA-GC1 for monitoring neoadjuvant chemotherapy response in gastric cancer Int J Surg 2023 109 5 1094 104 10.1097/JS9.0000000000000249 37222716
Guo X, Gao Y, Song Q, Wei J, Wu J, Dong J, et al. Early assessment of circulating exosomal lncRNA-GC1 for monitoring neoadjuvant chemotherapy response in gastric cancer. Int J Surg. 2023;109(5):1094–104.37222716 10.1097/JS9.0000000000000249
145. Nakamura K Zhu Z Roy S Jun E Han H Munoz RM An exosome-based Transcriptomic Signature for Noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a Multicenter Cohort Study Gastroenterology 2022 163 5 1252 e662 10.1053/j.gastro.2022.06.090 35850192
Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, et al. An exosome-based Transcriptomic Signature for Noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a Multicenter Cohort Study. Gastroenterology. 2022;163(5):1252–e662.35850192 10.1053/j.gastro.2022.06.090
146. Li L Zhang F Zhang J Shi X Wu H Chao X Identifying serum small extracellular vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer ACS Nano 2023 17 19 19197 210 10.1021/acsnano.3c05694 37750402
Li L, Zhang F, Zhang J, Shi X, Wu H, Chao X, et al. Identifying serum small extracellular vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer. ACS Nano. 2023;17(19):19197–210.37750402 10.1021/acsnano.3c05694
147. Li P Bai Y Shan B Zhang W Liu Z Zhu Y Exploration of potential diagnostic value of protein content in serum small extracellular vesicles for early-stage epithelial ovarian carcinoma Front Oncol 2021 11 707658 10.3389/fonc.2021.707658 34604046
Li P, Bai Y, Shan B, Zhang W, Liu Z, Zhu Y, et al. Exploration of potential diagnostic value of protein content in serum small extracellular vesicles for early-stage epithelial ovarian carcinoma. Front Oncol. 2021;11:707658.34604046 10.3389/fonc.2021.707658
148. Tao B Du R Zhang X Jia B Gao Y Zhao Y Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy J Control Release 2023 363 692 706 10.1016/j.jconrel.2023.10.007 37813124
Tao B, Du R, Zhang X, Jia B, Gao Y, Zhao Y, et al. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release. 2023;363:692–706.37813124 10.1016/j.jconrel.2023.10.007
